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Abstract 
Multiple Sclerosis (MS) is an immune mediated disease of the central nervous system 
(CNS). The aetiology is unknown, but environmental factors as well as multiple 
separate genetic loci contribute to the disease susceptibility.  Much research in the last 
decades has focused on the genetic basis of MS, but increasing evidence is emerging 
for major impact of environmental risk factors. Research on environmental risk factors 
is important since they offer a potential for disease prevention. The present study was 
designed to evaluate and add new knowledge to the role of environmental risk factors 
associated with the disease. The specific objectives were: A) Explore whether diet 
intervention with n-3 polyunsaturated fatty acids (PUFAs) could influence MRI 
disease activity, microglia activation, de- and remyelination in the cuprizone model for 
demyelination (Paper I). B) Assess if diet intervention with n-3 PUFAs from two 
different sources could prevent behavioural changes in the cuprizone model for 
demyelination (Paper II). C) Describe and characterise a case series of patients with 
co-occurrence of vitamin D dependent rickets (VDDR1) and MS (Paper III), D) Study 
if relapses in MS were associated with reactivation of latent Epstein-Barr virus (EBV) 
(Paper IV). E) Examine changes in gene expression in cortical lesions, normal 
appearing grey matter and meninges of MS patients. Perform an immunohistochemical 
characterisation of these brain sections and determine if active replication or latent 
infection with EBV was present in the sections examined (Paper V).  
The prevalence of MS is lower in the northern than in the southern parts of Norway. 
Since the prevalence of MS is known to normally increase with the distance from 
equator, this is an anomalous distribution of the disease compared to most other parts 
of the world. One widely accepted hypothesis for this distribution is that the 
inhabitants in the northern parts of Norway have a higher consumption of fatty fish 
than in the south, and that some substances in the fish (vitamin D or n-3 fatty acids) 
offer protection against MS. Two of the papers in this thesis investigate the role of 
nutrition and diet modification for the susceptibility to demyelinating diseases. We 
used an animal model for MS (the cuprizone model) in order to study how diet 
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modification with fatty fish or fish oils could influence the disease course, MRI 
activity, de- and remyelination in this animal model. Sixty-three mice were fed either a 
diet enriched with 1) salmon filets, rich in n-3 fatty acids, 2) cod liver oil rich in n-3 
fatty acids or 3) soybean oil rich in n-6 fatty acids. Cuprizone was added to the 
different diets. In the first study (Paper I), we found that the mice fed a salmon-
enriched diet had less MRI disease activity and demyelination than the two other 
groups. In the second study behavioural changes to cuprizone treatment were assessed 
with the elevated-plus-maze test (EPM). There were striking differences in weight 
loss, anxiety behaviour and activity levels, with a more favourable clinical outcome for 
the mice given a diet enriched with salmon filets (Paper II). The findings from these 
two studies indicated that diets rich in fatty fish could have protective effects against 
demyelination. There were no effects of giving n-3 supplements in the form of cod 
liver oil, indicating that other substances than the fatty acids could have accounted for 
the effect of a salmon based diet. Future studies should aim at isolating the active 
component in the fish diet, as this could offer a valuable treatment supplement for 
demyelinating diseases. 
Three of the papers deal with the most studied and recognised environmental triggers 
of MS, Vitamin D and Epstein-Barr virus (EBV). The third study (Paper III) identified 
three patients with a rare hereditary form of rickets (VDDR1). All of these patients 
later developed MS. These findings indicated rickets as a possible risk factor for MS 
and supported the theory that early childhood or the intrauterine periods are the main 
susceptibility periods for low levels of vitamin D.   
The next study (Paper IV) was designed to analyse whether there was an association 
between exacerbations in MS and reactivation of latent EBV. Sixty-one patients were 
followed for one year and blood samples were taken in the case of exacerbations or if 
magnetic resonance imaging (MRI) indicated evidence of new enhancing lesions. All 
the 61 patients (100%) were anti-viral capsid antigen (VCA) IgG positive, one (2%) 
was anti-VCA IgM positive and 60 (98%) were anti- Epstein Barr virus nuclear 
antigen (EBNA) positive. Mean anti-early antigen (EA)-D IgG at baseline was 0.57 
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(range 0.12-2.70) and at the time of exacerbations 0.61 (range 0.11-2.70). As 
demonstrated in earlier studies, all the patients in this sample had evidence of previous 
EBV infections, indicating that EBV could have a role in the pathogenesis of MS. 
There were, however, no signs of EBV-reactivation at the time of relapse. Thus, this 
study concluded that EBV reactivations do not play a significant role in MS 
exacerbations.  
The last study (Paper V) was designed to examine changes in gene expression in 
cortical lesions and in normal appearing grey matter from patients with MS. We 
observed a strong activation of immunoglobulin (Ig)-related genes in cortical sections 
of MS patients. The Ig-genes with the strongest activation were mostly variable and 
constant regions of the kappa and lambda light chains, but also included genes 
encoding heavy chains for IgM and IgG. No upregulation of Fc-receptor (FcR) genes 
was found. The cortical sections were immunohistochemically stained for plasma 
cells, Igs, T- and B-lymphocytes. The stainings revealed Ig-deposition in the meninges 
of the MS-patients compared to the controls. There were few B-lymphocytes and no 
B-lymphocyte follicles. Plasma cells were present in the meninges of all the MS 
patients but not in any of the controls. The activation of Ig-genes observed in the 
present study was highly interesting, as the synthesis of oligoclonal IgGs have been 
hypothesised to be caused by activation of EBV infected B-lymphocytes. The samples 
were screened for the presence of EBV by quantitative real time polymerase chain 
reaction (qPCR) and immunohistochemistry, but no evidence of active or latent EBV 
infection was detected. This study demonstrated that genes involved in the synthesis of 
Igs are upregulated in MS patients, and that this upregulation seems to be caused by a 
small number of plasma cells located in the meninges. Further, it concluded that EBV 
infected cells were not necessary for this Ig-upregulation. The findings indicated that 
the oligoclonal band (OCB) producing B-lymphocytes found in the cerebrospinal fluid 
(CSF) of MS-patients could have meningeal origin. 
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1. Introduction 
Multiple sclerosis (MS) is an immune mediated disease of the central nervous system 
(CNS). It is one of the most common causes of non-traumatic neurological disability 
among young adults in the western world. The cause of the disease is unknown, but it 
is widely accepted that environmental factors act in concert with a genetic 
susceptibility (Dyment et al. 2004; Ebers, 2008).  
Epidemiology 
MS is a disease affecting about 2.5 million people world-wide (Compston and Coles,  
2002) with a large variation in the geographical distribution. Northern and central 
Europe, USA, Canada, Australia and New Zealand are considered high risk areas, 
whereas most parts of Africa, Asia, Mexico and northern parts of southern America 
are considered low risk areas (Kurtzke, 1975; Compston and Confavreux, 2006). The 
disease affects women more often than men (Pugliatti et al., 2005; Grytten et al. 2006)
and the risk of MS seems to be increasing for women (Orton et al., 2006). This 
increase is not caused by genetic factors and indicates gender specific changes in 
environmental risk factors.  
Norway is considered a high-risk area for the disease and the prevalence seems to be 
increasing (Grytten et al., 2006). Increasing prevalence rates of MS have been reported 
in all the Norwegian counties that have been subject to repeated surveys. The 
prevalence of MS in Norway today is about 150/100000 (Grytten et al., 2006), 
indicating that about 7000 people are affected, with approximately 300 new cases per 
year (Torkildsen et al., 2007). The first studies on the distribution of MS in Norway 
found an east-west and a south-north gradient (Swank, 1950; Westlund, 1970). Two 
recent updates on the prevalence of MS (Grytten et al., 2006; Smestad et al. 2006) 
found that the prevalence of MS now is the same in the western and eastern part of 
Norway. The prevalence of MS seems, however, still to be lower in the northern parts 
of the country (Gronlie et al., 2000; Alstadhaug et al., 2005). Data from the most 
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recent epidemiological studies from Norway is given in Figure 1. Since the population 
in Norway is genetically homogenous, the differences in MS-prevalence seem to 
reflect that the exposition to environmental risk factors differs between the counties. 
The prevalence of MS is generally known to increase with the distance from equator, 
and the distribution in Norway is often refereed to as an anomalous distribution (Ebers, 
2008). It has been postulated that the coastal areas of Norway have a lower prevalence 
of MS due to higher fish consumption than the inland areas (Swank, 1950). Other 
studies from Norway have also indicated an inverse association between fish 
consumption and MS-susceptibility (Kampman et al., 2007). It has been demonstrated 
that the Sami population has a genetic profile that is less susceptible to MS than people 
with Caucasian heritage (Torkildsen et al., 2005; Harbo et al., 2007). Thus, the lower 
frequency of MS in the northernmost parts of Norway could also partly have been 
caused by a high number of people with Sami ancestry in the northernmost counties.  
18
Figure 1. MS distribution in Norway. The east-west gradient for MS postulated by 
Swank (1950) seems to have disappeared, but there is still a lower prevalence of MS in 
the two northernmost counties than in the rest of the country. The map is based on 
prevalence studies from the following counties of Norway: Hordaland county (Grytten 
et al., 2006), Oslo County (Smestad et al., 2006), Nord-Trøndelag County (Dahl et al., 
2004), Nordland County (Alstadhaug et al., 2005) and Troms- and Finnmark Counties 
(Gronlie et al., 2000). 
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Symptoms and clinical subtypes 
The disease manifests itself with only one symptom (monosymptomatic) in 80% of the 
patients and with multiple symptoms (polysymptomatic) in 20% (Myhr et al., 2001). 
Optical neuritis is the initial symptom in about 15-20%. Lesions can occur in the 
cerebrum, brainstem or cerebellum and the clinical symptoms reflect the part of CNS 
involved. Lesions in the pyramidal tract, including the spinal cord, typically present as 
weakness in upper or lower extremities (McDonald and Compston, 2006) while 
brainstem and cerebellar lesions typically produce symptoms of diplopia, vertigo and 
ataxia. In addition, sensory symptoms, pain, fatigue and cognitive problems are 
common (McIntosh-Michaelis et al., 1991; Rao et al., 1991; Beiske et al., 2004). The 
course and prognosis of the disease is unpredictable. Based on the initial disease 
course, MS has traditionally been classified into two main clinical patterns (Figure 2): 
1. Relapsing-remitting MS (RRMS) is the most common form of the disease, 
estimated to affect about 80-85% of the patients. It is characterised by 
unpredictable relapses with subsequent remissions. Deficits may either resolve 
completely or partially. With time, the recovery from each relapse is often 
incomplete. When disability progression occurs between relapses, the disease 
enters a secondary progressive (SPMS) phase. Secondary progression is found in 
40-50% of patients with RRMS after 15 years and in 80 % after 25 years with the 
disease (Noseworthy et al., 2006). 
2. Primary-progressive MS (PPMS) affects about 15-20% of the patients. It is 
characterised by a continuous increase in neurological deficits without clear 
relapses or periods of remission. A subgroup of this type is Progressive-relapsing 
(PRMS), characterised by increases in neurological deficits as well as 
superimposed relapses. This is the least common form of MS. 
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Figure 2. Clinical subtypes of MS. The figures show the two main clinical onsets of 
MS, RRMS and PPMS, and the subgroups, SPMS and PRMS, in each category. 
(Adapted from Compston and Confavreux, 2006). 
Relapsing-
remitting onset 
Progressive 
onset 
Relapsing 
remitting 
Secondary 
progressive           
Primary 
progressive 
Progressive 
relapsing 
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Clinical exacerbations 
Clinical exacerbations, or relapses, are defined as significant worsening of pre-existing 
symptoms or appearance of new neurological deficits in the absence of fever and 
lasting for more than 24 hours (Poser et al., 1983; McDonald et al., 2001; Polman et 
al., 2005). Stressful life events seem to correlate with exacerbations (Buljevac et al.,
2003) and there is also a significant association between systemic infections and the 
risk of relapses (Correale et al., 2006). Persistent parasitic infections may, on the other 
hand, protect against disease activity (Correale and Farez, 2007). Pregnancy has been 
shown to decrease the relapse rate, while it increases in the puerperium (Vukusic et al.,
2004). Despite these findings, the disease course is rather unpredictable and it has not 
been possible to predict relapse-risk in individual patients. 
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Pathology and pathological subtypes 
MS is usually viewed as an inflammatory demyelinating disease (Lassmann et al.,
2007). The histopathological characterisation is typically focal areas of myelin loss 
and partial axonal loss. The hallmark of the disease is formation of sclerotic plaques, 
which represent the end stage of a process with inflammation, de- and remyelination, 
astrocytosis, oligodendrocyte death and neuronal and axonal degeneration (Compston 
and Coles, 2008).  The plaques can be located everywhere in the brain or spinal cord, 
but are most frequently seen periventricular, in the optical nerve, cervical spine and in 
the subpial cerebral cortex.  
The immunological mechanisms leading to the disease are not completely understood, 
but many immunopathological processes are present. There is usually a marked 
inflammation in the early lesions, dominated by T-lymphocytes and activated 
macrophages and microglia, accompanied by a disrupted blood-brain barrier (BBB) 
(Kirk et al., 2003). Demyelination is accompanied by acute axonal injury and axonal 
loss (Trapp et al., 1998). The disease progression in MS is caused by accumulated 
axonal degeneration, and it has been debated whether inflammation is the primary 
event in MS or whether the inflammation is a secondary reaction to neurodegeneration 
(Compston and Coles 2008). Remyelination also occurs during the different disease 
stages, but it is most pronounced in the early phases of the disease course. In the 
progressive stages of MS, both in PPMS and SPMS, the pathological picture is 
different. In these forms, there are few active demyelinating plaques, but the pre-
existing plaques show evidence of gradual expansion (Prineas et al., 2001). As in 
RRMS, there is T-lymphocyte and microglia-infiltration present, but only few of the 
microglia contain myelin degradation products, indicating a slow rate of demyelination 
(Lassmann et al., 2007). Axonal loss seems to be the pathological substrate for the 
progressive disability seen in both these forms of MS (Tallantyre et al., 2009). 
Although it was previously regarded as a solely white matter disorder, newer studies 
have reported extensive grey matter involvement (Bo et al., 2003a; Bo et al., 2007). 
The cytoarchitecture of cortical lesions is usually well preserved and in the purely 
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cortical lesions, there is no significant T- or B-lymphocyte infiltration compared to 
control areas (Bo et al., 2003b). Secondary inflammatory changes are thus less 
pronounced in grey matter lesions. Plasma cells, T- and B-lymphocytes are, however, 
present in the meninges (Kutzelnigg et al., 2005). The grey matter plaques are 
generally less visible on MRI. 
Four distinctive pathological patterns have been suggested in early MS-lesions 
(Lucchinetti et al., 2000): 
  
Pattern I: Active demyelinated plaques associated with T-lymphocyte and 
macrophage dominated inflammation without antibody or complement 
deposition, but with relative preservation of oligodendrocytes. Loss of all 
myelin proteins appears to occur simultaneously.  
Pattern II: Active demyelination associated with T-lymphocyte and macrophage 
dominated inflammation. The pattern resembles pattern I, but is 
distinguished from other lesional patterns by pronounced 
immunoglobulin (Ig) reactivity. IgG and activated complement (C9neo) 
is found at sites of active myelin destruction.  
Pattern III: Active demyelination with preferential loss of myelin-associated  
glycoprotein (MAG) compared to proteolipid protein (PLP). The lesions 
contain infiltrates with T-lymphocytes, macrophages and activated 
microglia. There is evidence of oligodendrogliopathy and microglial 
activation as well as partial remyelination and oligodendrocyte apoptosis. 
The pattern is suggestive of a primary oligodendrocyte dystrophy. 
Pattern IV: Sharply demarcated plaques of demyelination. The oligodendrocytes do 
not show the morphological features of apoptosis, but oligodendrocyte 
death is revealed by DNA fragmentation. There is no complement 
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activation or preferential MAG loss and the inflammatory infiltrates are 
dominated by T-lymphocytes and macrophages.  
In the study that first identified these patterns, heterogeneity of lesion pattern was 
observed between patients, but not in the same individual, thus indicating MS as a 
heterogeneous disease. The pattern I and II resembled what is seen in T-lymphocyte- 
or T-lymphocyte and antibody-mediated autoimmune encephalomyelitis (EAE). 
Pattern III and IV were more consistent with a toxin-induced demyelination and 
seemed to be more in accordance with the cuprizone model (Torkildsen et al.,  2008a). 
The heterogeneity of MS lesions seems to disappear over time. In a recent study 
consisting of 93 tissue blocks from 39 MS patients, the authors did not find any signs 
of heterogeneity (Breij et al., 2008). Thus, the pattern with pathology-heterogeneity is 
probably an early event in the disease course. 
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Diagnosis 
The principle of diagnosing MS is to establish dissemination in time and space of 
lesions (Polman et al., 2005). This diagnosis can be based upon clinical evaluation 
alone or with the assistance of paraclinical features. According to the Poser criteria 
(Poser et al., 1983), clinical definite MS is defined as two or more relapses affecting 
two or more separate sites of the CNS and clinical evidence of two or more lesions. 
The last decade, these criteria have been replaced by the McDonald (McDonald et al.,
2001) and revised McDonald criteria (Table 1) (Polman et al., 2005). The principle is 
still to establish dissemination in time and space, but magnetic resonance imaging 
(MRI) and CSF-examination can substitute for one of the clinical episodes. The 
inclusion of the new criteria offers the potential for shorter time delay from the first 
symptoms to the diagnosis. This is of importance, as early therapy might be important 
for the long time prognosis of the disease (Compston and Coles, 2008).    
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Table 1. The 2005 Revisions to the McDonald Diagnostic Criteria for Multiple 
Sclerosis. (Polman et al., 2005).  
Clinical Presentation Additional Data Needed for MS 
Diagnosis 
Two or more relapses;  
objective clinical evidence of two or more lesions 
None, but paraclinical testing (MRI, 
CSF) should be done to exclude other 
diagnoses. 
Two or more relapses;  
objective clinical evidence of one lesion 
Dissemination in space, demonstrated 
by: MRI or Two or more MRI-
detected lesions consistent with MS 
plus positive CSF or Await further 
clinical relapse implicating a different 
site. 
One relapse; objective clinical evidence  
of two or more lesions 
Dissemination in time, demonstrated 
by MRI or Second clinical relapse.  
One relapse; objective clinical evidence  
of one lesion  
(monosymptomatic presentation;  
clinically isolated syndrome) 
Dissemination in space, demonstrated 
by MRI or Two or more MRI-
detected lesions consistent with MS 
plus positive CSF and Dissemination 
in time, demonstrated by MRI or
Second clinical relapse. 
  
Insidious neurological progression,  
suggestive of MS 
One year of disease progression 
(retrospectively or prospectively 
determined) and Two of the 
following: a) Positive brain MRI 
(nine T2 lesions or four or more T2 
lesions with positive VEP), b) 
Positive spinal cord MRI (two focal 
T2 lesions), c) Positive CSF 
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Treatment 
There exists no curative treatment for MS. A number of symptomatic and 
immunomodulatory treatments are however, available. Clinical exacerbations can be 
treated with high doses of methylprednisolone (MP), and the medication has been 
shown to improve symptoms and shorten time of disability after an acute exacerbation 
of the disease (Miller et al., 2000). Recent evidence also suggests that MP given in 
pulses every 4 weeks as add on to immunomodulatory treatment could lead to 
significant reduction in relapse-rate (Sorensen et al., 2009). Immunomodulatory 
treatment has been available as disease modifying treatment for RRMS since the mid 
1990’s. The treatment options are interferon-beta (IFNB) (Betaferon® (IFNB-1b), 
Avonex® (IFNB-1a), Rebif® (IFNB-1a)), and glatiramer acetate (Copaxone®). These 
medications have been shown to reduce the relapse-rate and MRI disease activity in 
MS (Paty et al., 1993; Johnson et al., 1995; Jacobs et al., 1996; PRISMS study group,  
1998). The main goals of the treatment are to inhibit disease activity, limit disability 
and delay disease progression (Miller et al., 2006). Natalizumab (Polman et al., 2006) 
and thereafter mitoxantrone (Hartung et al., 2002) are treatment options when relapse 
activity is still present, despite other immunomodulatory treatment. Mitoxantrone is 
also the only drug with indications for SPMS. There are a number of clinical trials 
underway, including many phase II and III trials, with promising new therapies for 
RRMS. Currently there are, however, no proven treatments for PPMS, indicating an 
urgent need for more research in this area (Compston and Coles, 2008).  
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2. Risk factors for MS 
MS is a complex disease where both genetic and environmental factors act in concert. 
It may be considered a heterogeneous disease with several clinical and pathological 
subtypes (Lucchinetti et al., 2000). This could also imply that there are subtypes of the 
disease, which differ in risk factors. Possible pathological and clinical subgroups are 
difficult to establish in epidemiological studies and have largely been ignored 
(Ascherio and Munger, 2008). When discussing risk factors for MS in this context, the 
disease is therefore referred to as a single entity. It is, however, possible that future 
studies will reveal subgroups of the disease with unique genetic and environmental 
risk factors.  
2.1 Genetic factors  
Although it is not considered a genetic disease, a genetic susceptibility is important for 
the development of MS. Familial aggregation has been accepted for a long time, and 
the strongest risk factor for this disease is a positive family history (Ascherio and 
Munger, 2008). The risk of MS is about 30 times higher among first-degree relatives 
than in the general population (Compston and Coles, 2002). It has been shown that 
both first, second and third degree relatives of patients with MS have an increased risk 
of the disease and the recurrence varies with relatedness (Dyment et al., 2004). If one 
person in a family has MS, the first-degree relatives have 1-3% risk of developing the 
disease (compared to 0.1% in the general population). For dizygotic twins, the risk is 
4% and for monozygotic, the risk is about 30% (Ebers, 2008). Adoption studies have 
shown that first-degree non-biological relatives of MS patients had the same risk of 
MS as the general population (Ebers et al., 1995), thus emphasising the importance of 
genetic factors. Similarly, in studies of half siblings, the intrafamilial environment had 
no effect (Ebers et al., 2004) and the risk of MS in stepchildren brought into a family 
with MS was also demonstrated to be the same as in the general population (Dyment et 
al., 2006). Thus, the aggregations of MS within families seem to be largely explained 
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by shared genes and not environmental changes in the microenvironment (Dyment et 
al., 2004). Environmental risk factors must therefore operate at a larger population 
level in genetically susceptible individuals. The association between genetic sharing 
and risk of MS is given in Figure 3. 
Figure 3. Prevalence rates of MS in the general population and in family 
members of MS patients. The error bars indicate the estimated 95 % confidence 
intervals.  (Adapted from Compston and Coles, 2008).  
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The susceptibility of MS has been linked to the humane leukocyte antigen (HLA) 
(Jersild et al. 1972). The markers have been refined as DR15 and DQ6 and the 
genotypes DRB1*1501, DRB*0101, DQA1*0102 and DQB2*0602 (Dyment et al., 
2004; Compston and Coles, 2008). This association is strongest in northern Europeans 
(Compston et al., 2008). The HLA-C5 (Yeo et al., 2007) and HLA-DRB1*11 ( 
Ramagopalan et al., 2007; Dean et al., 2008) loci seem, on the other hand, to offer a 
protective effect against MS-susceptibility. Recently, alleles within the interleukin-2-
receptor alpha gene (IL2RA) and the interleukin-7 receptor alpha gene (IL7RA) were 
also shown to be heritable risk factors for the disease (Gregory et al., 2007; Hafler et 
al., 2007; Lundmark et al., 2007). Development of MS is not likely to be attributed to 
a single gene, but to an interaction between many genes, where each gene has only a 
small effect. The fact that the rate for identical twins is less than 100% indicates that 
environmental factors must act in concert with the genetic susceptibility. Thus, genetic 
factors can not fully explain the geographic distribution or risk of developing MS in a 
population. Evidence from epidemiological and adoption studies indicate that the 
environmental factors act at a broad population level, rather than within the shared 
familial environment (Orton et al., 2008).  
2.2 Environmental factors 
The risk of MS differs between populations. In Norway, the Sami has had a much 
lower prevalence of the disease than the Norwegian population (Torkildsen et al., 
2005). It has also been demonstrated that Middle-East immigrants in Oslo have a 
higher prevalence of MS than other non-western immigrants (Smestad et al., 2006).  
This could indicate a genetic influence on the susceptibility for the disease in some 
populations, but it could also reflect that different populations are exposed to different 
environmental risk factors, or that the gene-environment interaction is important.  
The geographical distribution of the disease and change in risk among emigrants has 
given support to a role of environmental risk factors for the disease susceptibility. It 
has been demonstrated that migrants who move from an area where the disease is 
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common to an area where it is rarer have a decreased risk of disease, whereas people 
who move in the opposite direction retain their low risk of the disease. Their children 
are, however, at higher risk of MS (Gale and Martyn, 1995). These migrant studies 
indicate that environmental factors play a role in the susceptibility to MS and that they 
are particularly important during childhood.  
The prevalence of MS seems to be increasing in genetically homogenous populations 
(Grytten et al., 2006) and the female to male ratio is also growing (Orton et al., 2006). 
Similarly, there have also been reports of MS in populations who have earlier been 
regarded as genetically resistant to the disease, like the Sami population in Norway 
(Gronlie et al., 2000; Harbo et al., 2007). These changes in prevalence and sex ratio 
are difficult to explain by changes in genetic risk factors, as genetic changes occur 
over much larger time periods. Thus, this is regarded as implications for changes in the 
environmental risk factors. Since the prevalence is increasing in females, this could be 
attributed to changes in life-style particularly affecting women (Orton et al., 2006; 
Compston and Coles, 2008).  
Several candidate environmental triggers for MS, such as meat consumption, climate 
(Lauer, 1995), radon exposure (Bolviken et al., 2003), smoking (Riise et al., 2003), 
vaccination (Hernan et al., 2004) and psychological stress (Li et al., 2004), have been 
suggested. Many infectious agents have also been associated with the disease, and 
increased antibody titers have been reported for EBV (Bray et al., 1983; Sumaya et al.,
1985) measles virus (Panelius et al., 1971, Shirodaria et al., 1987), rubella virus 
(Shirodaria et al., 1987) and chlamydia pneumoniae (Sriram et al., 1999). Tetanus 
vaccination (Hernan et al., 2006) and increased levels of uric acid (Drulovic et al.,
2001; Rentzos et al., 2006) have on the other hand been proposed to reduce the disease 
risk. Most of the suggested environmental risk factors have not been replicated in 
follow-up studies or there is not enough evidence to give support or reject the 
hypotheses. Four environmental risk factors have, however, consistently been 
associated with the disease: Dietary factors, vitamin D, smoking and EBV-infection. 
The evidence for each of these factors is discussed briefly.  
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2.2.1 Diet 
Early epidemiological studies from Norway indicated that the prevalence of MS was 
lower in coastal villages with higher fish consumption than in the inland areas (Swank, 
1950; Westlund, 1970). These results have later been replicated in other countries 
(Esparza et al., 1995). Similarly, most population-based epidemiological studies have 
found an association between the incidence of MS and consumption of saturated fatty 
acids (Swank, 1950; Agranoff and Goldberg, 1974; Alter et al., 1974; Knox, 1977; 
Esparza et al., 1995). This led to the hypothesis that a diet rich in fish could have a 
protective role against MS. The results from case-control studies have, however, been 
conflicting. While one large cohort study found no effects of a high intake of PUFAs 
(Zhang et al., 2000), a recent case-control study from Norway (Kampman et al., 2007) 
indicated an inverse association between fish consumption and the risk of MS. It has 
been speculated if vitamin D or n-3 fatty acids in the fish could account for the 
protective effect.  
The results from intervention studies have been inconsistent. Some studies have 
indicated that supplementation with n-3 fatty acids could prevent relapses and slow 
disease progression (Ghadirian et al., 1998; Nordvik et al., 2000; Weinstock-Guttman
et al., 2005) while others have not been able to replicate these findings (Zhang et al., 
2000). Studies on n-6 fatty acids have also found conflicting results (Bates et al., 1978; 
Paty et al., 1978). In general high dropout levels and the use of different types and 
doses of PUFAs have prevented these studies from giving conclusive results (Farinotti
et al., 2007). Another problem is that the follow-up time has been short and that 
sensitive measures, like MRI, have not been applied to the studies. This could have 
made it difficult to detect differences between the treatment groups. Other studies have 
relied on a mixture of n-3 and n-6 PUFAs (Swank and Dugan, 1990). A main problem 
in these studies has been that different types and sources of PUFAs have been grouped 
together. Another problem is that the patients who persisted with diet modification 
could have had a milder disease course than the others (Esparza et al., 1995; Mehta et 
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al., 2009). There is need for more studies on this area, as 50-75 % of MS patients 
make use of special diets, especially diets with PUFAs (Farinotti et al., 2007). 
2.2.2 Sunlight and vitamin D 
Ecological studies have shown a strong correlation between low sunlight exposure and 
the risk of developing MS, and low sunlight exposure seems to be the strongest 
environmental factor associated with MS (Lauer, 1997). Several studies have found 
that outdoor activity is inversely correlated to the risk of developing the disease 
(Kampman et al., 2007). In another study skin cancer was found to be about 50% 
lower among patients with MS than expected (Goldacre et al., 2004). Skin cancer is 
directly linked to sun exposure, thus providing an indirect evidence for a possibly 
protective effect of sun exposure for the susceptibility to MS. There has also been one 
study on childhood sun exposure and risk of MS for monozygotic twins (Islam et al.,
2007). This study demonstrated that childhood sun exposure seemed to have a 
protective effect against MS in monozygotic twins, where the genetic susceptibility 
was the same. Sunlight is the major source of vitamin D, and this led to the hypothesis 
that the protective effect of sun exposure was caused by vitamin D synthesis and that 
vitamin D deficiencies could increase the risk of the disease (Ascherio and Munger, 
2007b).  
Studies on the animal model experimental autoimmune encephalitis (EAE) have 
demonstrated that supplementation of vitamin D can prevent both clinical and 
pathological evidence of disease activity (Lemire and Archer, 1991; Cantorna et al.,
1996), thus giving support to a protective role of vitamin D in MS. In a longitudinal 
cohort of 200 000 women (the Nurses health study I and II cohorts, 
http://www.channing.harvard.edu/nhs/), it was demonstrated that the relative risk of 
MS was 0.59 for women with a vitamin D intake >400 IU/day compared to women 
with a lower vitamin D intake (Munger et al., 2004). Similarly, in a nested case-
control study of 257 individuals with MS, it was demonstrated that the risk of MS 
declined with increasing serum levels of 25-(OH)D3 (Munger et al., 2006). The risk of 
MS was 62% lower among individuals within the highest quintile compared to the 
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lowest. In another study, high serum levels of 25-(OH)D3 were also associated with a 
lower incidence of MS, but in this study the association was only found among women 
(Kragt et al., 2008).  
The active form of vitamin D, mediates many of its effect on the immune system by 
binding to the vitamin D receptor (VDR). A number of studies have looked at 
associations between polymorphisms in the VDR and the susceptibility to MS. 
Although some studies have indicated an association (Fukazawa et al., 1999; Niino et 
al., 2000; Tajouri et al., 2005), others have not been able to replicate these findings 
(Steckley et al., 2000; Yeo et al., 2004; Partridge et al., 2004; Smolders et al., 2009). 
Some polymorphisms in the VDR seem, however, to be associated with reduced 
disease disability (Mamutse et al., 2008). A significant genetic influence determines 
the serum 25-(OH)D3 concentrations and it has also been demonstrated that 
polymorphisms in the CYP27B1 influences the 25-(OH)D3 status (Orton et al., 2008). 
In our study, we have described three patients with co-occurrence of mutations in the 
CYP27B1 and MS (Torkildsen et al., 2008c). Whether there is an association between 
these mutations or between polymorphisms in this enzyme and MS remains to be 
determined.  
There have been few intervention studies with vitamin D substitution and all of them 
have been uncontrolled, comparing the baseline or previous situation after intervention 
(Goldberg et al., 1986; Achiron et al., 2003; Wingerchuk et al., 2005; Kimball et al., 
2007; Burton et al., 2008). Since MS is a disease with an unpredictable disease course, 
it is not possible to draw affirmative conclusions from any of these studies, indicating 
an urgent need for well-designed clinical trials of high dose vitamin D substitution for 
MS.  
Vitamin D supplementation could be an effective way to reduce the prevalence of MS 
in a population. Human breast milk has a low content of vitamin D and infants that are 
not given supplementation with this vitamin are likely to develop low serum 
concentrations. There is an increased frequency of MS among people born in May, and 
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this could be caused by maternal deficiencies in vitamin D during the winter months 
(Willer et al., 2005; Ebers, 2008). The official recommendations for vitamin D intake 
are about 400 IU/day. These recommendations are, however, probably too low to give 
an optimal serum concentration of this vitamin (Bischoff-Ferrari et al., 2006). It has 
been estimated that an intake of 1000-4000 IU would be required to increase the serum 
levels of vitamin D to levels associated with MS protection (Vieth, 1999; Ascherio and 
Munger, 2008). As there has not been documented any adverse effects of vitamin D 
substitution, increasing the vitamin D intake in the population could offer a good 
strategy for primary disease prevention.  
2.2.3 Smoking 
Some epidemiological studies have indicated that smoking increases the risk of MS. A 
study from Norway (Riise et al., 2003) found that smokers had an almost doubled risk 
of MS. Childhood exposure to passive smoking has also been shown to double the risk 
of this disease (Mikaeloff et al., 2007). Based on such epidemiological studies, it has 
been estimated that up to 6% of all cases of MS could have been prevented if smoking 
was eliminated (Ascherio and Munger, 2008).  
Smoking has also been linked to an increased risk of early conversion to clinical 
definite MS (Di Pauli et al., 2008) and for transition to the secondary progressive form 
of the disease (Hernan et al., 2005). There have been many attempts to explain the 
association between smoking and MS, but at present it is not known why it exists. 
Smoking seems also to be associated with other autoimmune- and immune mediated 
diseases, like rheumatoid arthritis and systemic lupus erythematosus (Costenbader and 
Karlson, 2006) thus indicating that smoking could have a general effect on the immune 
system. Future studies on the mechanisms relating smoking to MS could lead to 
discoveries of new forms of disease prevention (Ascherio and Munger, 2008).  
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2.2.4 Epstein-Barr virus (EBV) 
The EBV is considered the most compelling infectious candidate for MS. EBV 
belongs to the herpes virus family and infection with the virus causes a lifelong carrier 
state. This leads to a continuous stimulation of the immune system and constant 
elevated antibody titers to EBV. Sero-epidemiological studies have consistently found 
that the EBV seropositive rate is higher in patients with MS than in controls (Bray et 
al., 1983; Sumaya et al., 1985; Myhr et al., 1998; Wandinger et al., 2000; Torkildsen
et al., 2008b). In children with MS, this association is even stronger (Pohl et al., 2006).
This high seroprevalence rate is not found for other viruses (Wandinger et al., 2000; 
Haahr and Hollsberg, 2006).  
There are many different immunological evidences linking EBV to MS. High titers of 
anti-EBV nuclear antigen (EBNA) antibodies have been shown to predict a higher risk 
of the disease (Levin et al., 2005). It has also been demonstrated that MS patients with 
high EBNA titers have more Gd-enhancing lesions on MRI than those with lower 
titers, as a measure of increased disease activity (Farrell et al., 2009). An increased 
humoral immune response to EBV has been found in the CSF of patients with MS 
(Bray et al., 1992). In addition increased CD4+ and CD8+ T-lymphocyte responses for 
EBV has been detected in the CSF (Holmoy et al., 2004) and in the blood of patients 
with MS (Hollsberg et al., 2003; Lunemann et al., 2006; Jilek et al., 2008). Further 
EBNA-1 specific T-lymphocytes have been shown to cross-react with myelin antigens 
(Lunemann et al., 2008). This supports the theory that clonally expanded EBNA1 
specific T cells could contribute to MS by cross-reaction with myelin antigens. 
A recent review (Ascherio and Munger, 2007a) concluded that the risk of MS is about 
20 times higher in people with a history of mononucleosis compared to EBV negative 
individuals. It has been suggested that the reason for this association is molecular 
mimicry between EBV and myelin components (Lang et al., 2002; Holmoy and 
Vartdal, 2004). There is, however, still no conclusive evidence that this mechanism is 
relevant for MS. The nature of the EBV makes it a plausible trigger of chronic 
inflammatory diseases. One study concluded that exacerbations in MS were associated 
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with evidence for serological reactivation of the virus.  Three other studies have not 
been able to replicate these findings (Buljevac et al., 2005; Torkildsen et al., 2008b; 
Farrell et al., 2009), and whether this finding was just an occasional association in a 
small sample set remains to be determined.  
A recent study, (Serafini et al., 2007) found EBV infected B-lymphocytes in the brains 
and meningeal tissue of the majority (21/22) of the MS patients examined. If these 
results were replicated, this would be compelling evidence for a role of EBV in the 
pathogenesis of this disease and it would have been a breakthrough in defining the 
pathogenesis of the disease. Unfortunately, these findings have not been replicated in 
five other studies (Hilton et al., 1994; Morre et al., 2001; Opsahl and Kennedy, 2007; 
Willis et al., 2009; Torkildsen et al., 2009c). Further, Willis and colleagues (2009) 
were not able to detect EBV in 12 MS specimens representing adjacent tissue blocks 
from the study by Serafini and colleagues (2007). This indicates that EBV seems not 
to be directly involved in MS pathology in the majority of MS patients. At present, the 
reason for these discrepant results is unknown. It appears that infiltration of EBV-
positive B-lymphocytes could be involved in a subgroup of patients, but this subgroup 
appears not to have distinct clinical characteristics.  
Many features of MS seem to be consistent with a pathogenic role of EBV and the 
similarities between EBV-infection and MS have been noticed for more than twenty 
years (Warner et al., 1981). The reduction of MS risk in emigrants from high to low 
risk areas, is, however, not easily explained by differences in age of EBV infection and 
it seems likely that other environmental factors, like vitamin D status, modify the 
susceptibility to EBV (Holmoy, 2008). It is also possible that some EBV-strains are 
more likely to increase the risk of MS than others (Munch et al., 1998), or that the 
association is caused by host factors which make peole vulnerable both to EBV-
infections and the disease (Niller et al., 2008). There exist no effective vaccine against 
EBV and the role of EBV in MS is only partially understood. Thus, at present it seems 
not possible to give a good protection against the possibly viral causes of the disease. 
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3. Aims of the study 
The main aim of this study was to investigate whether different environmental factors 
could influence the risk of developing MS, both in an animal model for the disease and 
in a patient population. The study consisted of five sub-studies: 
1. Explore if differences in diet fatty acid composition can influence MRI activity and 
the degree of de- and remyelination in the cuprizone model for demyelination. 
2. Assess whether differences in diet fatty acid composition can influence behavioural 
changes in the cuprizone model for demyelination. 
3. Describe and characterise patients with co-occurrence of VDDR1 and MS. 
4. Study whether EBV reactivation is associated with relapses in patients with MS.  
5. Examine changes in gene expression in cortical lesions, normal appearing grey 
matter and meninges of MS patients. Perform immunohistochemical 
characterisation of the brain sections examined and evaluate if EBV-infected cells 
are present. 
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4. Methodological considerations 
4.1 The cuprizone model for demyelination 
Although MS is exclusively affecting humans, there exist a number of animal models 
for the disease. The most widely used models are EAE (Rivers and Schwentker, 1933), 
Theiler’s virus induced encephalitis (Miller et al., 1997), and the cuprizone model 
(Blakemore, 1973). In EAE, immunisation with myelin antigens or passive transfer of 
myelin specific T- lymphocytes induces an inflammatory demyelination in the CNS of 
the animal. In Theiler’s virus induced encephalitis, infections of mice with the 
neurotropic picornavirus Theiler's murine encephalomyelitis virus (TMEV) leads to a 
progressive CD4 (+) T-lymphocyte-mediated demyelinating disease. The cuprizone 
model (Blakemore, 1974) is a model of toxic demyelination. In this model, young 
adult mice are fed with the copper chelator cuprizone (bis-cyclohexanone 
oxaldihydrazone). This leads to a consistent demyelination. Spontaneous 
remyelination can be observed as early as 4 days after withdrawal of the neurotoxin 
(Lindner et al., 2008), thus making the cuprizone model excellent for studying factors 
which can prevent demyelination and stimulate remyelination.  
Mice strain and cuprizone administration 
The cuprizone model was first established in Swiss mice (Carlton, 1967; Blakemore 
1972), but most recent publications have relied on the C57BL/6 strain (Matsushima 
and Morell, 2001; Hoffmann et al., 2008). The use of C57BL/6 mice offers a good 
potential of using the model in knockout gene studies. The dosage necessary to give 
demyelination is strain and age dependent (Irvine and Blakemore, 2006). The standard 
protocol applied the recent years has been feeding 8-weeks-old C57BL/6 mice with 
0.2 % cuprizone (w/w) for 6 weeks. It has been demonstrated that a higher degree of 
demyelination can be achieved by increasing the dosage to 0.3 % cuprizone (w/w) 
(Lindner et al., 2008). The major drawback, is that the mortality rate in the cuprizone 
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mice rises from <5% with 0.2 % cuprizone to 10-15% with 0.3 % concentration 
(Maren Lindner, personal communication.)   
Effects of cuprizone administration 
The administration of cuprizone causes cell death of the oligodendrocytes, which leads 
to a subsequent demyelination (Morell et al., 1998; Mason et al., 2004). It is not 
known exactly why administration of cuprizone only leads to a specific cell death in 
the oligodendrocytes, but cuprizone is a copper chelator, which in turn leads to 
inhibition of the copper dependent mitochondrial enzymes cytochrom oxidase and 
monoamine oxidase (Venturini, 1973; Matsushima and Morell, 2001). Hence, a 
plausible hypothesis is that disturbance in energy metabolism leads to apoptosis in the 
oligodendrocytes, which causes demyelination. If mice are exposed to a higher dose of 
cuprizone, this will lead to formation of megamitochondria in the liver, thus 
emphasising the role of mitochondrial dysfunction in this model. Although cuprizone 
is a copper chelator, the effect of cuprizone is not antidoted by administration of 
copper (Carlton, 1967). Another feature in this animal model for demyelination is that 
the mice develop hydrocephalus. Early experiments in the cuprizone model indicate 
that this development is caused by aqueductal stenosis (Kesterson and Carlton, 1970).     
Areas of demyelination and correlation to MS 
The demyelination was previously believed to predominantly affect the corpus 
callosum and superior cerebellar peduncles (Suzuki and Kikkawa, 1969; Matsushima 
and Morell, 2001). Newer studies, which have used immunohistochemical techniques, 
have however demonstrated extensive cortical demyelination in mice given cuprizone 
(Skripuletz et al., 2008). Thus, the pathological pattern may resemble what is found in 
MS (Bo et al., 2007). Since the cuprizone model is a model of toxic demyelination, 
leading to a primary loss of oligodendrocytes, the pathological pattern may resemble 
the type 3 or type 4 lesions in MS, as described by Luchinetti (Lucchinetti et al., 
2000). Cuprizone-induced demyelination is characterised by a microglia/macrophage 
response. However, the cuprizone model differs from MS and EAE in that the BBB 
remains intact (McMahon et al., 2002). Both MS and EAE involve complex 
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immunological processes and T-lymphocyte activation is frequently seen in both 
conditions. T-lymphocytes are, however, almost completely absent during cuprizone-
induced demyelination (Matsushima and Morell, 2001). The intact BBB could perhaps 
account for these differences. Recent evidence has challenged the hypothesis that MS 
is a result of primary autoimmune processes (Barnett and Prineas, 2004). Studies have 
indicated that, for at least some MS patients, apoptosis of oligodendrocytes seem to be 
the earliest change in newly forming lesions (Lucchinetti et al., 2000; Barnett and 
Prineas, 2004). Thus, the cuprizone model seems to offer a valuable supplement to the 
EAE model for studies of de- and remyelination.  
Behavioural responses  
Mice fed cuprizone exhibit weight loss, which is reversed when the cuprizone diet is 
discontinued (Franco-Pons et al., 2007; Xiao et al., 2008). The mice develop both 
motor and behavioural deficiencies. Morell and colleagues (1998) were the first to 
report behavioural deficiencies in cuprizone-treated animals. From visual observations, 
they reported that the cuprizone-treated animals appeared to have a lower activity level 
compared to the control animals. These observations have been replicated with 
standardised tests (Liebetanz and Merkler, 2006; Franco-Pons et al., 2007; Xiao et al., 
2008), and it appears that the C57Bl/6 mice given 0.2% cuprizone first go through a 
period with hyperactivity and decreased anxiety behaviour (after 3 weeks of cuprizone 
treatment) and then develop motor dysfunction (after 5 weeks). The motor 
dysfunctions seem to persist even 6 weeks after withdrawal of the neurotoxin (Franco-
Pons et al., 2007). 
Effects of chronic exposure 
Although the demyelination observed in the cuprizone model is usually reversible, 
chronic cuprizone exposure (≥12 weeks) leads to impairment of oligodendrocyte 
regeneration and insufficient remyelination (Armstrong et al., 2006). Mice that are 
chronically exposed to cuprizone (≥12 weeks) also experience tonic-clonic seizures 
upon stress-inducing stimuli (Kesterson and Carlton, 1972; Hoffmann et al., 2008).  
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These results also suggested that the seizures are a consequence of neuronal 
degeneration in the hippocampal formation (Hoffmann et al., 2008).  
Quantification of demyelination 
Histology 
Both luxol fast blue (LFB) staining, immunohistochemial studies and electron 
microscopy (EM) have been used to evaluate the degree of de- and remyelination in 
the cuprizone model (Matsushima and Morell, 2001; Lindner et al., 2008). It has been 
demonstrated that EM data correlated well with LFB myelin staining and 
immunohistochemical myelin protein staining (Lindner et al., 2008). In this study, 
immunohistochemical staining for myelin proteins was detected before significant 
remyelination is observed in EM. It seems therefore that immunohistochemical studies 
(Figure 4) may be sensitive for the detection of remyelination in the cuprizone model. 
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Figure 4. Stainings with luxol fast blue (LFB) and anti-proteolipid protein (PLP). 
The panel presents staining for myelin with LFB and anti-PLP from the corpus 
callosum of female C57Bl/6 mice. Normal myelin is shown in the controls; whereas 
the mice fed cuprizone for 6 weeks have a marked loss of myelin fibres. After one 
week of cuprizone withdrawal, it is possible to see some myelin-regeneration. 
(Adapted from Torkildsen et al., 2009a). 
 Controls 6 weeks of 
cuprizone 
1 week of cuprizone 
withdrawal 
LFB 
PLP 
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Magnetic resonance imaging (MRI) 
Animal models have proven to give valuable insight to confirm and validate the 
correlation between MRI findings and histopathology (Wu et al., 2008). Further, the 
use of MRI in the cuprizone model offers the potential of using MRI to follow the 
disease progression and monitor the effect of interventions (Figure 5). This could lead 
to a reduction in the number of animals necessary to study de- and remyelination. It 
has been demonstrated that MRI can be used as a reliable and valid surrogate marker 
of the extent of pathology in this model (Wu et al., 2008). Imaging may even be used 
for evaluating the dynamic process of de- and remyelination (Chen et al., 2007). 
However, more studies confirming the close relationship between MRI and histology 
are necessary before it can be used without histological verification of the results. 
Figure 5. T2 weighted MRI from C57Bl/6 controls and mice fed cuprizone for 5 
weeks. The picture shows hyperintense lesions (arrows) in the mice fed cuprizone for 
5 weeks. (Adapted from Torkildsen et al., 2009a) 
 Controls 5 weeks of 
cuprizone 
MRI 
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Behavioural testing 
MS leads to cognitive impairment in about 50 % of the patients (McIntosh-Michaelis 
et al., 1991; Rao et al., 1991). Only few studies have evaluated behavioural changes in 
the cuprizone model (Franco-Pons et al., 2007; Xiao et al., 2008). It has been 
demonstrated that the behavioural deficits induced by cuprizone treatment, correlate 
well with the extent of white matter demyelination in the animals (Franco-Pons et al., 
2007). Thus, behavioural testing may serve as a valuable surrogate marker for 
demyelination. 
Gene expression 
The cuprizone model has been used to identify temporal changes in levels of mRNAs 
during remyelination and demyelination (Jurevics et al., 2002; Bedard et al., 2007). 
Using these techniques, genes coding for myelin structural components have been 
found to be greatly down-regulated during demyelination and upregulated during 
remyelination (Jurevics et al., 2002). The cuprizone model has also been used to 
identify selective genetic markers for microglia activation (Bedard et al., 2007). The 
use of these methods offer the potential for a better understanding of both genetic 
mechanisms involved in microglia activation, de- and remyelination. Ultimately, this 
could lead to new therapeutic strategies for MS. 
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4.2 Study design of the diet intervention studies (article I 
and II) 
Mouse strain 
The present studies (article I and II) made use of the C57Bl/6 strain. It was chosen 
because it is the most common used strain in the cuprizone model and dose-response 
relations are well established (Lindner et al., 2008; Torkildsen et al., 2008a). The mice 
are genetically homogenous, thus reducing the intra-individual variability and the 
number of mice required for significant results. Our study was performed with female 
mice, while most researchers occupied with the cuprizone model have used male mice. 
Sex differences have been noted for SJL-mice exposed to cuprizone, but not for the 
C57Bl/6 strain, indicating that sex differences should not interfere with our results 
(Taylor et al., 2009). Since MS is a disease that affects women more often than men, 
one could argue that the use of female mice is even more transferable to human 
studies. Another reason for choosing female mice was that male mice have a more 
aggressive behaviour. Female mice were therefore chosen to avoid aggressive 
behaviour and subsequent injuries to the mice.  
Nutritional components 
The three diets used in the animal experiments were composed of 53.9 % dextrin, 18.0 
% protein, 9.0 % sucrose, 5.0 % α-cellulose, 5.0 % starch, 4.0 % lipids, 3.5 % mineral 
mix, 1.0 % vitamin mix, 0.3 % L-cystein, and 0.3 % choline. The diets differed mainly 
in the lipid source. The salmon based diet was made of salmon filets that were grinned 
and freeze dried and then grinned again to powder consistency before they were added. 
Thus, salmon was the main protein and lipid source for the mice in this group. The 
energy balance and balance between the different components were made to be as 
identical as possible (Table 2, 4). 
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Table 2. Energy balance in the different diets
Energy 
balance 
Salmon Cod liver oil Soybean oil 
Energy (J/g) 17832 17694 17771 
Fat (%) 5.6 5.0 5.0 
Protein (%) 21.2 17.7 18.1 
The soybean based diet used in this study was made to contain a composition of 
nutrients comparable to commercially available standard rodent diets (for example the 
Rat and mouse No.I maintenance diet, Scanbur, Special Diets Services, Karlslunde, 
Denmark). The standard n-6/n-3 ratios in these diets are about 10-13 (compared to 9.5 
in our diet). It could be argued that the studies should ideally include one group given 
standard rodent chow in addition to the soybean-oil group. By making the rodent diet 
ourselves we were, however, able to make sure that there were no main differences in 
the diets except for the lipid source. 
Lipid peroxidation 
Double bounds in PUFAs are unstable and easily oxidated by free radicals. It is 
therefore important to control that no significant peroxidation has occurred in the 
special diets. In our study, Thiobarbituric Acid Reactive Substances (TBARS) were 
measured to make sure there were no large differences in lipid peroxidation between 
the different diets (Table 3). The measurement of TBARS is one of the most 
commonly used methods for detection of peroxidation (Valenzuela, 1990). This is an 
in vitro indirect method of measurement. This could lead to an over- or 
underestimation of lipid peroxidation. Measurements of peroxide- and anisidine 
number in addition to TBARS could have given an even more sensitive and accurate 
measure (Brunborg, 2006).  
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Table 3. Results from analysis of TBARS, as a measure of peroxidation in the 
different diets.
 Salmon Cod liver oil Soybean oil 
TBARS 5.7 ng/g 3.7 ng/g 2.1 ng/g 
Table 4. The fatty acid content of the different diets. The results of the 
measurements of fatty acid contents are given in the following table. (Fatty acid 
content is given as g fatty acid/100 g feed, wet weight.) 
 Salmon Cod liver oil Soybean oil 
Σ saturated 7.6 8.1 7.9 
Σ monoenes 24.2 20.3 15.0 
  16:1n-7 1.5 3.0 0.2 
  18:1n-9 15.3 6.4 14.0 
  20:1n-9 2.5 3.9 0.1 
Σ n-6    5.9 1.4 22.9 
  18:2n-6 5.2 1.1 22.9 
  20:4n-6 0.2 0.3 N.D. 
Σ n-3 9.8 13.3 2.4 
  18:3n-3 2.1 0.4 2.4 
  20:5n-3 1.9 4.7 N.D. 
  22:5n-3 1.0 0.8 N.D. 
  22:6n-3 3.5 5.6 N.D. 
n-6/n-3 0.6 0.1 9.5 
Pantothenic acid 1.5 mg/100 g 1.6 mg/100 g 1.2 mg/100g 
Vitamin D3 4.3 μg/100 g 13.7 μg/100 g 2.6 μg/100 g 
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Administration 
In the cuprizone model for demyelination, the different diets are available ad libitum 
and cuprizone is added to the diets. It is therefore possible that cuprizone could have 
interacted with substances in the salmon-based diet or that a gastric interaction 
neutralising the neurotoxin could have occurred. This is a problem with all dietary 
intervention studies performed in this animal model. It is not possible to measure the 
amount of cuprizone in serum. It has, however, not been possible to antidote the effect 
of cuprizone in earlier studies in the cuprizone model, where the mice were given high 
doses of copper (Carlton, 1967; Kesterson and Carlton, 1972). These experiments were 
designed to give copper, which would interact with cuprizone in the stomach of the 
animals. The fact that these studies reported no effects of their interventions indicates 
that a gastric interaction is less likely.  
Study design 
The mice were grouped into 6 groups (three control groups given salmon, cod liver oil 
or soybean oil without cuprizone and three groups given cuprizone). MRI and 
behavioural testing was performed after 5 weeks of cuprizone administration 
(indicated with grey boxes). After 6 weeks of administration, half of the mice were 
sacrificed and after one week of remyelination, the remaining mice were sacrificed 
(Figure 6).  
Figure 6. Study design of the cuprizone experiments. The grey boxes indicate the 
week when the MRI and behavioural testing were performed. The asterisks indicate 
the time points when the mice were sacrificed. 
Control groups
Time (weeks)
1 2 3 4 5 6 7 8 9 10 11
Group 1, Salmon (N=9) * *
Group 2, Cod liver oil (N=9) * *
Group 3, Soybean oil (N=9) * *
Experimental groups 0 %
Time (weeks)
1 2 3 4 5 6 7 8 9 10 11
Group 1, Salmon (N=12) * *
Group 2, Cod liver oil (N=12) * *
Group 3, Soybean oil (N=12) * *
0 % Cuprizone 0,2% Cuprizone
0 % Cuprizone
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As there was no intraindividual variability in the control groups for weight gain, 
behaviour, MRI activity, demyelination, inflammation or astrocytosis, future studies 
can probably reduce the size of the control groups. The sizes of the intervention groups 
were large enough to detect significant changes in de- and remyelination and we lost 
only one mouse during the experimental procedure. It would, depending on outcome 
measure and expected effect sizes, be advisable to increase the size of the cuprizone-
intervention groups in future studies in order to increase the likelihood of reaching 
significant differences.  
Behavioural testing and MRI 
The elevated plus maze (EPM) test was administered for behavioural testing and T2 
weighed MRI sequences were used as MRI measures of disease activity. 
Histochemistry and immunohistochemistry 
For quantification of de- and remyelination, the tissue sections were stained with LFB. 
In addition immunohistochemistry was used for detection of demyelination (anti- 
PLP), BBB-damage (anti-fibrinogen), astrocytosis (anti-glial fibrillary acidic protein; 
GFAP) and microglia activation (anti-MAC-3) (Table 5).  
Table 5. Primary antibodies used in the diet intervention study.  
Antigen Detection Species/isotype Dilution Primary 
antibody 
Source Pre-treatment 
PLP Myelin Mouse IgG2a 1:1000 24 h, 
4°C 
Serotec Citrate buffer  
15 min. 
GFAP Astrocytes Mouse IgG1 1:2000 ½ h,  
22°C 
Dako EDTA buffer  
15 min. 
Fibrinogen BBB-damage Rabbit 
polyclonal 
1:20000 ½ h, 
22°C 
Dako EDTA buffer  
15 min. 
MAC-3 Microglia/macrophage 
infiltration 
Rat IgG1,K 1:200 24 h 
4°C 
BD 
Bioscie
nces 
Citrate buffer  
15 min. 
Abbreviations: GFAP=Glial fibrillary acidic protein, PLP=Proteolipid protein 
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Dose translation to human studies 
It has been common to extrapolate the dosage used in animal studies to humans by 
simply multiplying with body weight. A more correct dose translation is probably the 
use of normalisation of body surface area (BSA). This method has been demonstrated 
to correlate across several species with oxygen utilisation, basal metabolism, blood 
volume, renal function, plasma proteins and caloric expenditure (Reagan-Shaw et al.
2008). It has also been applied to antineoplastic drugs and has been shown to correlate 
with maximum tolerated doses in rodents and humans (Freireich et al., 1966).  
The formula for dose translation based on BSA is given with the following formula 
(Reagan-Shaw et al., 2008): 
KmHuman
KmAnimalkgmgdoseAnimalkgmgdoseestimatedHuman )/( )/(   ×=
where Km is equal to body weight (kg) divided by BSA (m2). For humans the weight 
is approximately 60 kg with a BSA of 1.6 m2, giving a Km factor of 37 and for mice 
the weight is 0.02 kg with a BSA of 0.007 m2, giving a Km factor of 3. 
The major drawback with this formula is that BSA is estimated with a formula 
incorporating measures of body weight and height, the Du Bois height-weight formula
(Du Bois and Du Bois, 1915), from which the constants were derived from only 9 
patients: 
0.007184(cm)height   (kg))( 0.7250.4252 ××= weightbodymBSA
It is likely that more reliable conversion-methods will be developed in the future, but 
currently the BSA-calculations are far superior to body-weight extrapolations 
(Reagan-Shaw et al., 2008). 
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4.3  Vitamin D 
Vitamin D is a fat-soluble vitamin. It can be considered a hormone rather than a 
vitamin, as it can be synthesised in the body, is released in the circulation and has 
distinct target organs (Gillham et al., 2001). It is included in the vitamin group, as it 
becomes an essential dietary factor when endogenous synthesis is inadequate to meet 
the physiological requirements. It is usually synthesised in the skin from 7-
dehydrocholesterol upon exposure to ultraviolet-B radiation. Ultraviolet light causes 
scission of the B-ring of 7-dehydrocholesterol to form previtamin D3. This is followed 
by a spontaneous rearrangement to cholecalciferol, or vitamin D3. The vitamin can 
also be obtained from the diet and dietary sources become increasingly important 
when there is little ultraviolet radiation. The vitamin D3 is biological inactive and must 
be metabolised to its biological active form. The active form of vitamin D3, 1,25-
dihydroxycholecalciferol (1,25-(OH)2D3), is produced by a 2-step hydroxylation; first 
at the 25 position in the liver by the mitochondrial cytochrome P450 27 A1 
(CYP27A1) isozyme. 25-(OH)D3 is then hydroxylated at the 1α position in the kidney 
by the cytochrome P450 27B1 (CYP27B1) isozyme. This leads to the formation of 
1,25-(OH)2D3. The 1,25-(OH)2D3 form of the vitamin is the most active form and it is 
500 times more potent than 25-(OH)D3. Vitamin D in the form of 1,25-(OH)2D3 is a 
strong immunomodulator. It works on the vitamin D receptor (VDR), expressed on T- 
lymphocytes, macrophages and dendritic cells (Lin and White, 2004). The serum level 
of 1,25-(OH)2D3 is normally well regulated and is within the normal range even in 
people who are vitamin D deficient (Ascherio and Munger, 2008).  
Mechanisms of vitamin D in the immune system 
1,25-(OH)2D3 regulates calcium and phosphate homeostasis. As shown in figure 7, the 
classical target tissues are bone, kidney and intestine. It has also been reported to have 
a number of other functions, including inhibition of proliferating malignant cells 
(Raghuwanshi et al., 2008). It mediates many of its functions by binding to the VDR. 
It has been demonstrated that the VDR is present on T-lymphocytes and that 1,25-
53
(OH)2D3 can inhibit T-lymphocyte proliferation and activation (Bhalla et al., 1983). 
This suppressive effect is followed by a decrease in interleukin-2 (IL-2) and 
interferon-γ (IFN-γ) mRNA levels (Bhalla et al., 1986). Due to the effect of 1,25-
(OH)2D3 on various parts of the immune system, the vitamin has been implicated in 
various autoimmune and immune-mediated diseases. It has been used with great 
success in a variety of animal models for diseases, including experimental lupus 
erythematosus (Lemire et al., 1992), arthritis (Cantorna et al., 1998) and EAE 
(Cantorna et al., 1996).  
Requirements of vitamin D 
Sunlight exposure is the main source of vitamin D in most parts of the world. It has 
been estimated that one day of sun exposure is equivalent to a single dose of 10 000 to 
25 000 IU of vitamin D (Holick, 2005). Fish oils and egg yolk are natural dietary 
sources of vitamin D (Figure 7). In the northern parts of the world, there is no 
ultraviolet radiation between November and April, thus making exogenous supply 
necessary to avoid vitamin D deficiencies (Gillham et al., 2001). Seasonal variation, 
time spent outdoors and skin pigmentation will influence the vitamin D serum levels. 
Babies born in the autumn and breast fed during the winter will also have low levels of 
vitamin D, if they are not given supplementation, as breast milk contains only small 
amounts of the vitamin.  
Increased exposure to sunlight or increased dietary intake of vitamin D increases 
serum levels of 25-(OH)D3, thus making it a useful measure of vitamin D nutritional 
status. Serum level of 25-(OH)D3 is considered the best indicator of vitamin D 
deficiency. It is highly sensitive to vitamin D intake and sun exposure and is a marker 
of vitamin D availability to tissues (Ascherio and Munger, 2008). The cut-off values 
for normal 25-(OH)D3 status are, however, under debate (Zittermann, 2003). It is 
generally agreed that serum levels of less than 20-25 nmol/L indicate severe deficiency 
associated with rickets. 50 nmol/L has been suggested as the lower limit of the normal 
range, but PTH levels seem not be normalised before vitamin D levels reach at least 80 
nmol/L (Thomas et al., 1998). A daily dose of 1000 IU of vitamin D seems to be 
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required to bring the concentration in a population up to 75 nmol/L 25-(OH)D3 in at 
least 50% of the population (Bischoff-Ferrari et al., 2006). A very high intake of 
vitamin D can, on the other hand, lead to vitamin D toxicity. This can result in bone 
loss, kidney stone formation and calcification of heart and kidneys. Vitamin D toxicity 
has not been observed as a result of sun exposure and it is very seldom occurring with 
an intake of less than 10 000 IU/day (Holick, 2007). In general, a daily intake of 4 000 
to 10 000 IU per day is safe for young adults (Vieth, 2001; Heaney et al., 2003) and 
serum concentrations above 600 nmol/L are required to elicit hypercalcemia 
(Hathcock et al., 2007).  
Several factors other than sun exposure and dietary intake also determines the levels of 
circulating 25-(OH)D3. Women have normally lower serum levels than men and skin 
colour, amount of body fat and age have also been shown to determine the 
requirements of vitamin D (Myhr, 2009). Finally, polymorphisms in the 1-alfa-
hydroxylase (CYP27B1) are also significantly associated with the 25-(OH)D3
concentration (Orton et al., 2008), indicating that the vitamin D regulation is under 
important genetic influence.   
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Figure 7. Vitamin D metabolism. The figure demonstrates the major sources of 
vitamin D, how it is metabolised and its major biological effects (Modified from 
Crawford et al., 2006).  
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4.4 Epstein-Barr virus (EBV) and EBV serology 
The EBV was first discovered in 1964. It is a virus in the herpes family and infections 
lead to a lifelong carrier state. It has a 173-kb DNA genome and is capable of infecting 
B- and T-lymphocytes, squamous epithelial cells in the oro- and nasopharynx, 
glandular epithelium of the thyroid, stomach and salivary gland, smooth muscle cells 
and follicular dendritic cells (Gulley, 2001). In Norway, about 15-25% of children 
below the age of 5 years are infected and by the age of 30, about 90-95% are carriers. 
When children become infected with the virus, these infections usually produce no 
symptoms or only mild flu-like symptoms. The virus causes infectious mononucleosis 
in 35-50% when the infection occurs during adolescence. Most of the symptoms of 
mononucleosis are attributable to the T-lymphocyte response of the infection (Cohen, 
2000).  
Mechanism of infection 
The virus is transmitted in salvia. Epithelial cells or resting B-lymphocytes in the 
orophaynx are infected. The cells then either undergo lytic infection with the 
production of more viruses or express the latent viral proteins (Cohen, 2000). 
Cytotoxic T-lymphocytes and Natural Killer (NK) cells regulate the latently infected 
B-lymphocytes. Cell lysis is associated with the release of virions with viral spread to 
lymphoid tissue. Further replication leads to viremia with infection of the liver, spleen 
and B-lymphocytes in the peripheral blood. Cytotoxic T-lymphocytes and NK cells 
eventually reduce the number of infected B-lymphocytes (Figure 8). Since an infection 
with the virus causes a carrier state, it remains dormant in B-lymphocytes for the rest 
of a person’s life. EBV infected cells are rare in healthy virus carriers (~1-50 per 106
cells) and cannot be analysed directly (Kuppers, 2003). The virus can reactivate and is 
then found in salvia of the infected person. These reactivations usually occur without 
clinical symptoms. 
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Figure 8. EBV infection in humans. The figure shows how the EBV is transmitted by 
salvia to the epithelium in oropharynx. From here it can infect resting B-lymphocytes 
who are either transformed to a lytic or resting (latent) phase. The primary infection is 
eventually controlled by cytototxic T-lymphocytes and NK cells. (Modified from 
Cohen,  2000). 
Latent and lytic cycle 
The latent infection is characterised by a limited expression of latent genes, where the 
virus does not replicate, but persists within the host cells (Bergallo et al., 2007). The 
EBV encodes nine latency-associated proteins. Six of them are located in the nucleus 
(EBV nuclear antigens; EBNAs) and three of them are located in the membrane (latent 
membrane proteins; LMPs) (Thorley-Lawson, 2001). Three different latency forms 
have been recognised (Table 6) (Thorley-Lawson, 2001; Kuppers, 2003). In the type I 
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pattern only EBNA1 is expressed, in the type II pattern EBNA1 and LMP1 and/or 2 
are expressed and in type the III pattern EBNA1, EBNA2, EBNA3a-c, EBNA-LP, 
LMP1 and LMP2 are expressed. The type III pattern is also known as the growth 
program, because EBV-transformed B-lymphocytes proliferating in vitro have this 
gene expression pattern. In addition, it is recognised a latency pattern 0, in which EBV 
protein expression is limited to LMP2 (Bergallo et al., 2007).  LMP2A is the only gene 
product that is consistently detected in healthy carriers. The lytic cycle is initiated by 
the transcription of the EBV immediate early BZLF1 gene. The gene is a hallmark of 
lytic infection, and is used to distinguish between the latent and lytic stage (Kubota et 
al., 2008).   
EBV-associated diseases 
The EBV is a cofactor for the development of a number of inflammatory and 
neoplastic diseases. The virus is known to be able to cause infectious mononucleosis if 
the disease occurs in adolescence. Infectious mononucleosis is a predisposing factor 
for the development of Hodgkin’s disease. EBV is present in 40-60% of the cases of 
the disease and it is predisposing to both the EBV positive and negative Hodgkin’s 
disease (Thorley-Lawson, 2001). In Hodgkin’s disease, the type II pattern of gene 
expression is usually found. EBV is also present in almost all endemic cases of 
Burkitt's lymphoma and 20-30% of cases outside the endemic areas (Rickinson and 
Kieff, 2001). In Burkitt's lymphoma, only EBNA-1 (type I pattern) is expressed. The 
virus is also found in almost all undifferentiated forms of nasopharyngeal carcinoma 
and has then typically the latency II pattern of gene expression (Sudo et al., 1997). 
Finally, T-lymphocyte immunosuppressive therapy given to patients after 
transplantation is associated with increased risk of lymphoproliferative diseases (post-
transplant lymphoproliferative diseases; PTLD) (Kuppers, 2003). These diseases are 
almost always of B-lymphocyte origin and positive for EBV (Knowles, 1998). The 
majority of PTLD cases have the latency III pattern of gene expression. 
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Table 6. EBV latency forms. (Adapted from Kuppers, 2003). The table illustrates the 
latent protein expression of the EBV virus in different latency forms. 
Latency 
form 
EBERs EBNA1 LMP1 LMP2A EBNA2 EBNA3/ 
EBNA-
LP 
Occurrence 
0 + N.D. - + - - Memory B-cells in 
peripheral blood, healthy 
carriers 
I + + - - - - Burkitt's lymphoma 
II + + + + - - Hodgkin’s lymphoma and 
nasopharyngeal 
carcinoma 
III + + + + + + Post-transplant lymphoma
IV N.D. N.D. - N.D. + N.D. Infectious mononucleosis
Abbreviations: EBERs= Epstein-Barr virus encoded RNA, EBNA= Epstein Barr virus nuclear antigen, LMP= 
Latent membrane protein, N.D=Not determined 
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4.4.1 Detection of EBV 
Epstein-Barr virus encoded RNA (EBER) in situ hybridisation 
This is considered the gold standard for detection of EBV in tissue samples (Ambinder 
and Mann 1994; Gulley, 2001). EBER transcripts are expressed in latently infected B-
lymphocytes at high levels, thus making this a very sensitive detection method. There 
are two main pitfalls with this technique. First, there is a possibility of false negative 
hybridisation results as a result of RNA degradation (Gulley, 2001). This can be 
avoided by running a hybridisation in parallel to ensure that RNA is preserved. 
Secondly, there is a risk of false positive results if the results are not adequately 
distinguished from background lymphocytes and artefacts.  
Immunohistochemistry  
This method can be used to detect viral proteins expressed on EBV-infected cells. 
These stainings, especially LMP1, have proven to be nearly as effective as in situ 
hybridisation for identifying EBV in PTLD, Hodgkin’s disease and infectious 
mononucleosis (Lones et al., 1997). True LMP1 positive stainings are granular in 
character and are localised to the cytoplasm. False positive signals have been reported 
from eosinophils, plasma cells, cells of the nervous system and poorly fixated cells 
(Gulley, 2001).  
Reverse-transcriptase polymerase chain reaction (RT-PCR) 
The use of this technique offer the potential for identifying and distinguishing between 
different latency forms of the infection and also to distinguish between latently 
infected cells and cells in the lytic phase. The most common targets are EBNA1 and 2, 
LMP2A and BZLF1 (Gulley, 2001). Although this method is not used on a routine 
basis, it has just been validated with a high degree of sensitivity and specificity 
(Kubota et al., 2008). 
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Serology 
Antibodies to several antigen complexes may be measured in the serum of patients. 
Immunosuppressed patients can have inconsistent responses to EBV and serology is 
not a reliable marker of infection in these patients. In healthy individuals, serology is 
considered the gold standard to detect acute versus remote infections (Gulley, 2001). 
The following antibodies are usually measured: IgM and IgG to the viral capsid 
antigen (VCA), IgM to the EBV nuclear antigen (EBNA) and IgG to the early antigen 
(EA). IgM to the viral capsid antigen (VCA) appears early in the infection and 
disappears after 4-6 weeks. IgG to the viral capsid antigen (VCA) appears in the acute 
phase of the infection. It reaches a peak after about 2-4 weeks and persists for the rest 
of life. The EBV nuclear antigen (EBNA) appears 2-4 months after the acute infection 
and persists for life. IgG to the early antigen (EA) appears in the acute phase and 
usually falls to undetectable levels after 3-6 months. With viral reactivations, the anti-
EA-IgG titer increases. 
Figure 9. Serological reactions to active (lytic) and latent EBV infection. The 
figure illustrates the production of antibodies to different components of the EBV virus 
during the acute viral infection and in the latent phase.  
Abbreviations: EA=Early antigen, EBNA=EBV nuclear antigen, VCA=Viral capsid antigen,  
VCA IgG
EBNA
months1 2 3
VCA IgM
EA IgG
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4.5 Microarray 
In a gene expression microarray, thousands of genes can be monitored to study the 
effect of a disease on gene expression. A number of different microarray platforms 
have been established. The microarrays are glass microscope slides, silicon chips or 
nylon membranes where thousands of different genes are attached to different 
locations. The principle of running a cDNA microarray experiment is simple (Figure 
10). First RNA is purified from control and experimental samples. Then reverse 
transcription is used to convert the extracted RNA into cDNA. This is labelled with 
fluorescent probes. It is usual to use Cy3 for the controls (which have a fluorescent 
emission wavelength corresponding to the green part of the light spectrum) and Cy5 
for the experimental samples (corresponding to the red part of the light spectrum). The 
two-labelled samples are mixed and incubated into the microarray. The labelled 
samples then bind to the sites on the array corresponding to the genes expressed.  
  
Figure 10. The principle of gene expression analysis by DNA microarray 
technology. (From Khan et al., 1999) 
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Gene expression studies in MS 
Microarray techniques were first applied to MS brain tissue in 1999 (Whitney et al.,
1999). Since then, a number of studies have used these techniques to study gene 
expression in demyelinated lesions (Tajouri et al., 2003), normal appearing white (Zeis 
et al., 2008) and grey (Dutta et al., 2006; Dutta et al., 2007) matter. The main findings 
in the published microarray studies on MS brain tissue are given in table 7. The studies 
differ in the number of genes examined and in characterisation of the brain tissue 
material, thus making a direct comparison between the studies difficult. 
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Table 7. Main findings and characteristics of the studies using microarray 
techniques on MS brain tissue. 
Reference Number of 
patients 
Genes 
examined
Tissue used Brain area Main findings 
Whitney et al., 
1999 
1 MS (PP),  
0 controls 
5 000 Acute lesions vs. 
NAWM 
NA Inflammation related genes 
upregulated 
Whitney et al., 
2001 
2 MS (PP, RR), 
3 controls 
2 798 WM lesions NA 5-lipooxygenase upregulated in WM 
lesions 
Lock et al. , 
2002 
4 MS (SP),  
2 controls 
7 000 Lesions vs. 
Control. Acute vs. 
Chronic 
NA Granulocyte stimulating factor 
upregulated in active lesions. 
FcγR upregulated in chronic lesions. 
Tajouri et al. , 
2003 
5 MS (SP),  
0 controls 
5 000 WM lesions, 
chronic and active 
WM lesions 
and 
NAWM 
69 common genes with increased 
expression in chronic and acute 
lesions and 70 transcripts uniquely 
expressed in each. 
Mycko et al., 
2003 
4 MS (SP),  
0 controls 
588 Lesions (chronic 
active vs chronic 
inactive) 
NA Upregulation of inflammatory and 
apoptosis related genes 
Graumann et 
al., 2003 
10 MS (SP, 
PP),  7 controls 
3 528 NAWM vs Ctrl 
WM 
Subcortical 
white 
matter 
Upregulation of genes involved in 
maintenance of cellular homeostasis 
and neuroprotection in NAWM 
Mycko et al., 
2004 
4 MS,  
0 controls 
588 Chronic active vs- 
chronic inactive 
lesions 
NA Upregulation of inflammatory and 
apoptosis related genes 
Lindberg et 
al., 2004 
6 MS (SP),  
12 controls 
12 556 Lesions vs Ctrl. 
WM 
NAWM vs. Ctrl. 
WM 
NA Cellular immune response in 
NAWM 
Humoral immune response in lesions
Dutta et al., 
2006 
6 MS (SP, PP), 
6 controls 
33 000 NAGM vs. Ctrl. 
GM 
Motor 
cortex 
Mitochondrial dysfunction in 
NAGM in MS 
Dutta et al., 
2007 
6 MS (SP, PP), 
6 controls 
33 000 NAGM vs. Ctrl 
GM 
Motor 
cortex 
Activation of the ciliary neurotropic 
factor signalling pathway 
Zeis et al., 
2008 
11 MS (SP, PP, 
PR),  
8 controls 
3 528 NAWM vs Ctrl 
WM 
Subcortical 
white 
matter 
Upregulation of genes involved in 
anti-inflammatory mechanisms in 
NAWM 
Torkildsen et 
al., 2009c 
6 MS (SP, PR), 
8 controls 
27 868 NAGM vs. GML 
vs Ctrl GM and 
meningeal tissue 
Cortical and 
meningeal 
tissue 
Upregulation of Ig-related, but not 
FcγR-genes. 
  
Abbreviations: NA=Not applicable, SP=Secondary progressive, PP=Primary progressive, PR=Progressive 
relapsing, GM= Grey matter, GML=Grey matter lesions, NAGM=Normal appearing grey matter, 
NAWM=Normal appearing white matter, WM=White matter.  
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The use of the microarray method raises many methodological considerations. The 
most important are discussed briefly:  
Normalisation and statistical analysis 
A number of different normalisation methods exist, depending on the system used. 
Global normalisation is often applied to microarray systems covering a large number 
of genes (Kinter et al., 2008). In our study, inter-array quantile normalisation was 
performed in order to minimise the effect of external variables introduced into the 
data. Examination of similarities and differences in global gene expression profiles of 
the samples was done by principal component analysis (PCA).  Identification of 
probes that differed significantly in expression level (i.e. hybridisation signal intensity) 
between sample groups was carried out by significance analysis of microarrays (SAM) 
(Tusher et al., 2001), comparing the expression levels of all probes in one group with 
those of the other. The SAM analysis threshold was set to a q-value of five (Storey, 
2003). 
Standardisation 
There exist many different platforms for RNA profiling. They differ with respect to the 
number of genes analysed, in the length of cDNA probes and how RNA is processed 
before labelling (Kinter et al., 2008). This makes it difficult to compare the results 
from microarray studies directly (Comabella and Martin, 2007).  Our study was 
performed with the Applied Biosystems (AB) Expression Array system, which is 
based upon chemiluminescence detection (emission of electromagnetic radiation 
during the course of a chemical reaction). This method does not require excitation and 
results in low background noise, thus enhancing the sensitivity of the array (Figure 
11). The AB human microarray contains 31,700 probes against 27,868 genes, as well 
as about 1,000 control probes.  
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Figure 11. The principle of the chemiluminescence detection method. First 
digoxigenin (DIG) labelled cDNA hybridises to the microarray. Then DIG antibody-
alkaline phosphatase conjugates and finally an enhancer interacts with the activated 
chemiluminescent substrate, which in turn produces light. (Adapted from Applied 
biosystems, 
http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldo
cuments/cms_040420.pdf)
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Immunohistochemical characterisation of the material 
An important issue in microarray studies is identification of the cellular composition of 
the samples examined (Kinter et al., 2008). An immunohistochemical characterisation 
of both the control and MS-samples is therefore important. In our study, the control 
and MS-samples were screened for demyelination (anti-PLP), B- and T-lymphocyte 
infiltration (anti-CD20 and anti-CD3), plasma cell accumulation (anti-CD138), Ig-
deposition (anti-IgA, -IgG, -IgM, -Kappa, Lambda) and latent EBV infection (anti-
EBNA2 and anti-LMP1). The primary antibodies used in this study are given in table 
8. 
Table 8. Primary antibodies used in the microarray study.  
Antigen Detection Species/isotype Dilution Primary 
antibody 
Source Pre-treatment 
PLP Myelin Mouse IgG2a 1:2000 24 h Serotec 95 % ethanol 10 min. 
CD20 B-lymphocytes mouse IgG Prediluted 10 min Dako 95 % ethanol 10 min. 
CD3 T-lymphocytes rabbit polyclonal 1:800 1 h Sigma 95 % ethanol 10 min. 
CD138 Plasma cells mouse IgG 1:400 1 h Serotec 95 % ethanol 10 min. 
IgA, -IgG, -IgM, 
-Kappa, Lambda 
Immunoglobulins rabbit polyclonal 1:800 1 h Dako 95 % ethanol 10 min. 
EBNA2 EBV-EBNA2 mouse IgG 1:50 1 h Abcam 95 % ethanol 10 min. 
LMP1 EBV-LMP1 mouse IgG Prediluted ½ h Abcam 95 % ethanol 10 min. 
Abbreviations: EBNA= Epstein Barr virus nuclear antigen, LMP= Latent membrane protein, PLP= Proteolipid-
protein
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Sample and case selection 
It is important to avoid false positive results because of sample and case selection. 
Gender, age differences and medical treatment could influence the microarray results 
(Kinter et al., 2008). In our study, brain samples from six patients with MS and eight 
control patients without any signs of neurological disease were obtained from the 
Dutch Brain Bank, the Netherlands for microarray examination. The mean age of MS 
cases was 49.2 years (range 41-58) with a mean post-mortem delay of 8.6 hours (range 
8-11). The mean age of the control cases were 81.9 years (range 74-89) with a mean 
post-mortem delay of 7.3 hours (range 4-15). For qPCR validation, five additional MS 
patients and four additional controls were included. The mean age of these MS patients 
were 57.8 years (range 34-75) with a mean post-mortem delay of 10.7 hours (range 
6.3-18.0) and the mean age of these controls were 73.7 years (range 57-82) with a 
post-mortem delay of 6.7 hours (range 5.4-8.2). The possible implications of the age 
differences between the MS and control samples are discussed in Chapter 5.  
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5. Summary of results and general discussion 
5.1 Summary of results 
5.1.1 Effects of diet intervention on MRI activity, de- and 
remyelination in the cuprizone model for demyelination (article I) 
The aim of this study was to analyse if diets with a different composition of PUFAs 
could influence demyelination, as measured by histopathology and MRI, and stimulate 
remyelination in cuprizone fed mice, a widely used animal model for de- and 
remyelination.  
Sixty-three female C57Bl/6 mice were fed with 0.2% cuprizone on three different diets 
that consisted of the same ingredients, except the lipid source which came from 1) 
salmon fillets rich in marine n-3 PUFAs, where the salmon filets served both as a lipid 
and protein source, 2) cod liver oil rich in marine n-3 PUFAs, or 3) soybean oil rich in 
n-6 PUFAs. MRI was performed after 5 weeks of continuous cuprizone treatment. 
After 6 weeks, half of the animals were sacrificed and the corpus callosum was 
examined using LFB histochemistry and immunohistochemistry for PLP, GFAP, 
fibrinogen and MAC-3. After one week of remyelination, the rest of the mice were 
sacrificed and the corpus callosum examined with the same histo- and 
immunohistochemical techniques. 
After 5 weeks of cuprizone-treatment the mice fed salmon-cuprizone had a 
significantly lower hyperintense lesion volume on T2-weighted MRI than the two 
other groups (P<0.0005). The mice given salmon-cuprizone had significantly less 
demyelination after 6 weeks of cuprizone treatment, as measured with LFB 
(P<0.0005) and PLP (P=0.014). There was less infiltration of mac-3 immunopositive 
cells in the corpus callosum of mice fed salmon-cuprizone compared to the mice given 
soybean oil-cuprizone (P=0.041), but not compared to mice receiving cod liver oil-
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cuprizone (P=0.073). The salmon-cuprizone group had also enhanced remyelination 
compared to the cod liver oil-cuprizone group (LFB; P=0.003, PLP; P=0.018). 
Immunostaining for fibrinogen revealed no sign of BBB damage in the cuprizone-
treated mice or in the controls at any of the time points. 
5.1.2 A salmon based diet protects mice from behavioural changes 
in the cuprizone model for demyelination (article II) 
The aim of this study was to evaluate whether diets with n-3 PUFAs from two 
different sources could influence behavioural changes induced by demyelination in 
cuprizone pre-treated mice, compared to a control diet with an n-3/n-6 ratio more like 
a western diet. The cuprizone model is well suited for studying dietary factors that 
may influence neuropsychological dysfunction induced by demyelination (Franco-
Pons et al., 2007; Xiao et al., 2008). Our hypothesis was that supplementation with 
omega-3 PUFAs would have a protective effect on demyelination, leading to less 
dysfunction in the two n-3 groups than in the control group.  
Female mice were fed three different diets enriched with 0.2% cuprizone. The diets 
consisted of the same ingredients, except the lipid source, which came from 1) salmon 
fillets rich in marine n-3 PUFAs, where the salmon fillets also served as a protein 
source, 2) cod liver oil rich in marine n-3 PUFAs, or 3) a control diet containing 
soybean oil rich in n-6 PUFAs. The mice were weighed twice weekly throughout the 
experimental period. After 5 weeks of continuous cuprizone treatment, animal 
activities were assessed with the elevated plus-maze (EPM) test and after 6 weeks the 
mice were sacrificed and tissue sections from their brains were stained with LFB.  
The mice fed salmon-cuprizone had significantly less demyelination than the two other 
groups (P<0.001). They had also more visits in both open and closed arms of the EPM 
than the other cuprizone treated groups (P’s<0.0001). In addition they had more entries 
in the open arms than both the cod liver oil-cuprizone (P<0.02) and the soybean oil-
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cuprizone treated mice (P<0.0001). Their weight loss was also smaller than the other 
cuprizone-treated mice (P<0.0001). 
5.1.3 Vitamin D-dependent rickets as a possible risk factor for 
multiple sclerosis (article III) 
This article is a case study of three patients in two families with co-occurrence of MS 
and VDDR1. VDDR1 is a very uncommon genetic subtype of rickets, caused by a 
mutation in CYP27B1. The active form of vitamin D, 1,25-(OH)2D3, is produced by a 
two-step hydroxylation, first at the 25-position in the liver by mitochondrial CYP27A1 
and then at the 1α-position in the kidney by CYP27B1. Thus, CYP27B1 is the key 
enzyme in determining the rate of 1,25-(OH)2D3 production. Vitamin D is emerging as 
an important cofactor for the susceptibility to MS (Ascherio and Munger, 2007b). 
There have, however, not been any studies on the possible association between 
hereditary forms of rickets and this disease. The prevalence of MS in Norway is 1.5 
per 1000 people (Torkildsen et al., 2007). The prevalence of VDDR1 is not known, 
but we were only able to identify three patients diagnosed with VDDR1 at Haukeland 
University Hospital, which serves a population of 460,000 people.  
All three patients identified in this study had VDDR1 verified by genetic testing and 
fulfilled the Poser criteria for MS (Poser et al., 1983). Two of the patients had 
undergone magnetic resonance imaging, which confirmed the diagnosis of long-lasting 
MS. The patients in our case series had been given cholecalciferol or ergocalciferol 
(vitamin D3 and D2) supplements since childhood. Blood samples from two of the 
patients were available and they had normal and above normal levels of 1,25-(OH)2D3. 
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5.1.4 Epstein-Barr virus reactivation and multiple sclerosis (article 
IV)  
The aim of this study was to look for evidence of reactivation of latent EBV infection 
during MS-exacerbations. Several lines of evidence have implicated an association 
between EBV infection and the risk of MS. All patients have evidence of previous 
EBV infection (Myhr et al., 1998), the risk of MS is increased after infectious 
mononucleosis and there seems to be an age-dependent relationship between EBV 
infection and development of MS (Ascherio and Munger, 2007a). One study has also 
suggested that exacerbations in MS are associated with reactivation of latent EBV 
infection (Wandinger et al., 2000). These findings could, however, not be reproduced 
in another study (Buljevac et al., 2005), and whether EBV plays an underlying role as 
an activator of MS remains controversial.  
Sixty-one patients with definite RRMS according to the Poser criteria were available 
from a clinical trial on interferon treatment (Myhr et al., 1999). All patients had 
definite RRMS according to the Poser criteria (Poser et al., 1983). Mean age was 34.9 
years (range 21-48) with mean expanded disability scale (EDSS) score of 2.8 (range 0-
5.5). The patients were followed for one year and blood samples were drawn at 
baseline, months 3, 6 and 12 and in case of clinical exacerbations. MRI was performed 
at baseline, monthly during the first six months and at month 12. Blood samples for 
analysis of anti-EA-D IgG were drawn at the time of clinical exacerbations or when 
the MRI examination revealed new T1 gadodiamide-enhancing lesions. All included 
patients were analysed for evidence of previous EBV infection by measuring IgM and 
IgG antibodies against VCA and EBNA-1. Twenty-three baseline-paired exacerbation 
samples were quantitatively analysed to examine whether exacerbations in MS were 
associated with a change in anti-EA-D IgG ratio.  
All the 61 patients in our study (100%) were anti-VCA IgG positive, one (2%) was 
anti-VCA IgM positive and 60 (98%) were anti-EBNA positive. Mean anti-EA-D IgG 
at baseline was 0.57 (range 0.12-2.70) and at the time of exacerbations 0.61 (range 
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0.11-2.70). Wilcoxon signed rank test revealed no differences between the 23 baseline 
and paired samples (P=0.58).  
5.1.5 Upregulation of immunoglobulin-related genes in cortical 
sections from multiple sclerosis patients (article V) 
In the present study, we have compared global gene expression in normal appearing 
grey matter and grey matter lesions of the cortex of MS patients as well as comparing 
grey matter samples in MS- and control patients. The brain sections examined were 
then immunohistochemically characterised and qPCR and immunohistochemistry was 
performed for detection of both potential EBV transcripts and proteins. 
Microarray-based global gene expression profiling is increasingly used to study 
potential genes involved in the pathogenesis of MS. The method offers the potential 
for a better understanding of the pathogenesis involved in MS (Kinter et al., 2008). 
Previous studies have mainly focused on white matter tissue. To date, there have only 
been two studies on global gene expression in the cortex of MS patients (Dutta et al., 
2006, Dutta et al., 2007).  
For the microarray examination, brain samples from six MS patients and eight controls 
were available from the Dutch brain bank, the Netherlands. All microarray 
experiments were performed using the Applied Biosystems Expression Array system. 
The results were then validated using Taqman qPCR. qPCR was also used for 
detection of latent (EBNA1, EBNA2, LMP1, LMP2) and lytic (BZLF1) EBV 
transcripts in the samples examined. Finally, immunohistochemistry was used for 
detection of demyelination (anti-PLP), Igs (anti-IgA, IgG, IgM, kappa, lambda), B-
lymphocytes (anti-CD20), T-lymphocytes (anti-CD3), plasma cells (anti-CD138), and 
latent EBV-infected cells (anti-EBNA2 and anti-LMP1).  
We observed a strong activation of Ig-related genes in the cortical sections of MS 
patients. Among these, the genes with the strongest activation were variable and 
constant regions of the kappa and lambda chains, but also included genes encoding 
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heavy chains for IgM and IgG. No upregulation of Fc-receptor genes was found. The 
results were verified with Taqman qPCR. The cortical sections were then 
immunohistochemically stained for plasma cells, Igs, T- and B-lymphocytes. The 
stainings revealed Ig-deposition in the meninges of the MS-patients compared to the 
controls. There were few B-lymphocytes and no B-lymphocyte follicles. Plasma cells 
were present in the meninges of all the MS patients but not in any of the controls. 
The activation of Ig-genes observed in the present study is highly interesting as the 
synthesis of oligoclonal IgGs have been hypothesised to be caused by activation of 
EBV infected B-lymphocytes. The sensitivity of the qPCR for EBV-transcripts was 
tested using the EBV positive cell line B95.8 in dilutions with the EBV-negative cell 
line CRL-1593.2. It was possible to detect EBV-positive cells at concentrations down 
to 1:1000-10 0000. The sensitivity of the immunohistochemistry was tested using the 
EBV-positive cell line B95.8 as a positive control. We then screened for the presence 
of this virus in our MS- samples using both techniques, but were unable to detect signs 
of active or latent EBV.  
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5.2 General discussion 
5.2.1 Article I and II 
Outcome measures 
MRI                
T2 weighted MRI was taken after 5 weeks of cuprizone administration. The 
examination revealed large group differences in volume of hyperintense lesions. Other 
sequences could have differentiated if this partly resulted from increased intra- or 
extracellular fluid volume. It would especially have been interesting to use 
magnetisation transfer ratio (MTR) to visualise myelin loss and repair (Zaaraoui et al.,
2008) and to include more time points for MRI analysis.  
Histology and immunohistochemistry          
LFB and PLP have been proven to be reliable markers for the degree of demyelination 
in this animal model (Lindner et al., 2008). Thus, inclusions of other methods, like EM 
would probably have added only limited information. It would have been interesting to 
add an immunohistochemical staining for oligodendrocytes, such as anti-neuritic 
outgrowth factor (NOGO). Since cuprizone is thought to affect the oligodendrocytes 
directly, this could have added more knowledge to the effects of dietary interventions.  
Behavioural responses and weight loss         
The mice were weighed twice weekly and their behavioural responses to cuprizone 
administration were assessed with the EPM test. The EPM test is primary used to 
measure anxiety behaviour, but it can also be used to measure activity levels (Lister, 
1987). Thus, the present study (article II) was able to draw conclusions on group 
differences in weight loss, activity levels and anxiety behaviour. This behaviour study 
was largely explorative and future studies should include a larger battery of behaviour 
assessment tests. It would especially be interesting to include open-field assessment, 
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the rota-rod test and functional observation battery since these are tests that have been 
evaluated in the cuprizone model (Golub et al., 2004).   
Validity and reliability  
One of the main concerns with intervention studies in the cuprizone model is that 
cuprizone could theoretically interact with the intervention substance in the stomach of 
the animal (Zhang et al., 2008). Thus, the validity of the experiment for MS would be 
low. However, two studies have found that it is not possible to antidote the effect of 
cuprizone by co-administration of dietary copper supplements (Carlton, 1967; 
Kesterson and Carlton, 1972). In addition mice exposed to dietary interventions with 
the salmon based diet had less behavioural changes than the other mice (Torkildsen et 
al., 2009b) and cuprizone is not known to affect other cells in the CNS than 
oligodendrocytes. The best way to make sure there was no antidote effect would have 
been to measure the serum-cuprizone level in each animal. Unfortunately, there are 
currently no methods for this detection.  
The diets were available ad libitum and a possible confounder could be that the energy 
content or fatty acid composition differed between the diets. There was, however, little 
variation between the diets in this aspect. It could also be argued that the salmon fed 
mice ate more of the chow than the other groups and thus had less weight loss. Since 
this would also have led to more ingestion of cuprizone, this should have given them 
more demyelination than the two other groups. The fact that they had less weight loss 
and demyelination than the two other groups, seem to confer that the salmon based 
diet offered a protection against the effects of cuprizone. 
Another concern is how valid the cuprizone model is for MS. In the cuprizone model, 
there is no disruption of the BBB and little inflammation (Torkildsen et al., 2008a), 
which are prominent features of MS (Lassmann et al., 2007). The processes 
underlying de- and remyelination are probably well suited for studies in the cuprizone 
model. Histopathological analysis indicate that the cuprizone model has a pathological 
pattern which could resemble the type III or IV lesions described by Lucchinetti and 
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colleagues (2000). Thus, the pathological pattern resembles some aspects of MS, and 
the model seems to be a valuable supplement to EAE. There have been few 
intervention studies in the cuprizone model and the validity of the model for 
therapeutic interventions are yet to be determined. If the results from the diet 
intervention studies were replicated in another animal model for MS, like the EAE-
model, this would significantly strengthen the validity of the conclusions for MS.  
The two dietary intervention studies contained a number of measures to increase the 
reliability of the results. Since the salmon based diet had a positive influence on 
weight loss, behavioural changes, MRI activity, demyelination and microglia 
activation, the conclusion that salmon offers a protective effect against the 
neurotoxicity of cuprizone seems to be consistent independent of the measures used. In 
order to increase the reliability of the experiment, the results should be confirmed in a 
new study. 
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5.2.2 Article III 
As this study suggests that rickets and low levels of 1,25-(OH)2D3 are possible risk 
factor for MS, it would have been interesting to include repeated measures of the 
vitamin D status in these patients. The patients were however, diagnosed with vitamin 
D dependent rickets in the 1950s and analysis of the active components of vitamin D 
(25-(OH)D3 and 1,25-(OH)2D3) were not available at the time. The diagnosis was 
based on clinical signs of rickets, changes in the meta-epiphysis on x-ray, 
hypophosphatemia and hypocalcaemia; it was confirmed in 2003 with genetic testing.  
All the patients have been treated with supplementation of vitamin D since the time of 
diagnosis. We have performed a detailed analysis of vitamin D status in the patients 
(vitamin 25-(OH)D3 and 1,25-(OH)2D3). Their vitamin D levels were close to normal 
or above the reference values at the time of measurement due to their substitution-
therapy. Blood samples were available for two of the patients, one receiving 
substitution with Rocaltrol (Roche) and one receiving AFI-D2 forte (Nycomed 
Pharma). Rocaltrol contains 1,25-(OH)2D3 and AFI-D2 forte contains 25-(OH)D2. For 
the patient receiving substitution therapy with Rocaltrol, the 25-(OH)D3 level was 6,5 
nmol/L and the 1,25-(OH)2D3  level was 42 nmol/L. For the patient receiving AFI-D2
forte, the 25-(OH)D3 level was 672 nmol/L and the 1,25-(OH)2D3 level was 24 nmol/L. 
The normal reference value for 25-(OH)D2 and 1,25-(OH)2D3 taken together is 30-150 
nmol/L.  
Since all the patients in this case series had a mutation in the CYP27B1, responsible 
for the final hydroxylation to 1,25-(OH)2D3, supplementation with 25-(OH)D2 in the 
form of AFI-D2  forte would not increase the level of  the most potent form of vitamin 
D3, 1,25-(OH)2D3. Further AFI-D2 forte contains ergocalciferol (vitamin D2) and not 
cholecalciferol (vitamin D3) and it has been suggested that vitamin D3 has a greater 
bioefficiacy than vitamin D2 (Houghton and Vieth, 2006).  It is therefore possible that 
the patients have had a sub-optimal treatment of their rickets and that this has given an 
increased risk of MS. Since they have received substitution therapy, the findings may 
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also indicate that low level of vitamin D in early childhood, or maybe even in the 
intrauterine period, could account for increased susceptibility to MS observed in 
individuals with low levels of circulating vitamin D. 
5.2.3 Article IV 
A crucial issue regarding this study is the value of performing isolated EA-D IgG as a 
measurement of EBV-reactivation. The study by Wandinger and colleagues (2000) 
and Buljevac and colleagues (2005) included both measurements of anti-EA-D IgG 
and PCR-samples in selected patients. Inclusion of both these parameters could have 
increased the sensitivity of our study. In relation to reactivations and exacerbations in 
MS, the immunological response is however probably of greater importance than the 
viral load in serum. Buljevac and colleagues (2005) were in their study able to find 
viraemia on PCR in only 3 samples, despite an elevated immune response against anti-
EA-D IgG in many more samples. It is well known that chronic T-lymphocyte 
responses against EBV proteins of the early replication phase can prevent viral 
replication (Cohen et al., 2000, Buljevac et al., 2005). Thus, including PCR analysis 
would not necessarily provide more information regarding the relationship between 
exacerbations and reactivation. 
One of the strengths of our study compared to the two earlier papers on this subject 
(Wandinger et al., 2000, Buljevac et al., 2005) was that we were able to include 
systematic MRI-scans. Although Buljevac and colleagues (2005) were able to perform 
three MRI-scans from a selected sample of 37 patients, their study did not include 
systematic MRI-scans. In our study, we have followed all the 61 patients included with 
MRI-scans at 8 time-points (month 0, 1, 2, 3, 4, 5, 6, 12). This could potentially have 
detected subclinical lesion activity and increased the likelihood of detecting a 
correlation between rises in anti-EA-D IgG titers and exacerbations.  
In the study by Buljevac and colleagues (2005) there was a tendency towards a higher 
number of gadolinium enhancing lesions in the EA+ than the EA- group. Only three 
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samples in our study showed, however, signs of elevated anti-EA-D IgG titers and 
there was no sign of increased disease activity or a higher number of gadolinium 
enhancing lesions in this group. This further emphasises the fact that there seems to be 
no correlation between rises in anti-EA-D IgG titers and disease activity in our patient 
sample.  
5.2.4 Article V 
Sample and case selection 
The availability of affected MS tissue is limited. Brain biopsies from MS patients are 
very rare and most studies rely on post-mortem material. It is therefore possible that 
other genes are up- or down regulated in earlier phases of the disease course. RNA 
degrades shortly and it is important to use cases with a short post-mortem interval. The 
control cases should be at the same age as the samples (Lu et al., 2004).  It is also 
important to use control samples from the same brain areas as the MS lesions to avoid 
false results due to brain region differences (Stansberg et al., 2007). Differences in 
gene expression could be due to an up- or down regulation in the cells in the region, 
but it could also be caused by differences in cellularity (Kinter et al., 2008).  
Immunohistochemical characterisation of the material with markers for gliosis, 
demyelination and inflammation is therefore important for the interpretation of the 
data (Kinter et al., 2008). In addition, some of the genes found differently expressed 
between the samples should be validated using qPCR.  
Eight Ig-related genes were selected for validation by TaqMan qPCR. This validation 
confirmed significant upregulation of the IGKC, IGHG1 and IGKV41 genes in the MS 
samples. Thus, the upregulation of Ig-related genes seems to be consistent. 
In our study, it was difficult to obtain age-matched MS and control samples. In general 
it is difficult to obtain brain tissue from MS patients and very few centres have frozen 
tissue available, as we used in our study. Age differences between the MS- and control 
samples are known to affect the expression of some genes, like anti-oxidative stress 
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genes and genes involved in mitochondrial function (Lu et al., 2004). On the other 
hand, there are no reports of changes in Ig-expression with increasing age. In order to 
exclude an age effect, qPCR was performed on additional samples not included in the 
microarray assay. In these samples, the age was overlapping between the MS- and 
control groups and we did not observe any age-effect on Ig upregulation in these qPCR 
analyses. Thus, the upregulation of Ig-gene related probes seemed to be attributable to 
MS and not age-related changes in gene expression in our study.  
On the global level we were unable to detect systematic differences between GML and 
NAGM. The findings may be influenced by heterogeneity of the samples and batch 
effects interfering with our results. Since there is little inflammation in cortical MS-
lesions (Bo et al., 2003b), one would especially expect genes involved in myelin 
production to be substantially downregulated in GML compared to NAGM. It has, 
however, been demonstrated that there is substantial remyelination at the lesion border 
of cortical lesions (Albert et al., 2007; Stadelmann et al., 2008), and this could have 
made it more difficult to detect downregulated genes in the lesions. Microarray studies 
with laser dissected material could maybe increase the likelihood of detecting these 
changes in gene expression. 
Immunohistochemistry 
All the MS and control cases were screened for degree of demyelination (anti-PLP), 
immunoglobulin deposition (anti-IgA, IgG, IgM, Kappa, Lambda), plasma cells (anti-
CD138), B (anti-CD20)- and T-lymphocytes (anti-CD3) with immunohistochemistry. 
This was done to detect cells that could account for the differences in gene expression 
observed in the MS and control samples. 
Our immunohistochemical staining revealed no B-lymphocyte follicles in any of the 
MS-samples examined. There have been three articles reporting findings of these 
follicles in MS-patients (Serafini et al., 2004; Magliozzi et al.; 2007, Serafini et al., 
2007). The reason for this discrepant result could have been caused by the small 
number of tissue blocks examined in our study, or that ectopic follicles have only 
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developed transiently and disappeared at the time of death (Serafini et al., 2007). Since 
the immunohistochemical sampling in our study was limited, the most plausible 
hypothesis seems to be that there could have been B-lymphocyte follicles located in 
other blocks not examined. Since B-cell follicles have been demonstrated to be the 
main focus of EBV-persistence (Serafini et al., 2007), it could also be argued that the 
chance of identifying EBV-infected cells is very small when B-lymphocyte follicles 
are not present. A recent study questions the findings by Serafini and colleagues 
(2007). Despite looking for evidence of EBV-infections in some of the same tissue 
blocks, they were not able to find evidence for EBV-infection (Willis et al., 2009). Our 
study was not designed to give a detailed investigation of the possible presence of B-
lymphocyte follicles or EBV-infection in the CNS of MS-patients. It seems, however, 
that persistent EBV infection did not cause the Ig-upregulation found in our sections, 
as neither B-cell follicles nor EBV-infected cells were found in close proximity to the 
microarray sections examined. 
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5.3 Future perspectives 
Paper I and II 
These studies indicate that dietary intervention could offer a therapeutic strategy in 
demyelinating diseases. The results need to be replicated in the cuprizone model and 
preferably in other animal models for MS, like the EAE model. Since the cuprizone 
model seems to be a model with primary oligodendrocyte death, the effects in a 
primary inflammatory model, like EAE would be very interesting. It would also be 
interesting to study if diet intervention could improve the disease course if it is 
introduced after cuprizone administration is started. In our study, the mice were 
already fed the three different diets at the time of cuprizone administration. If the 
results are consistent in different animal models for MS, human intervention studies 
should be considered.  
Although we were able to perform a detailed analysis of energy balance, vitamin- and 
fatty acid content in the different diets, no blood samples were collected from the mice 
in this experiment. Thus, we were not able to measure if n-3 fatty acids from the 
salmon diet had a better uptake than the n-3s from cod liver oil. Since some human 
studies have indicated that the source of n-3s could influence their uptake (Visoli et 
al., 2003; Elvevoll et al., 2006; Harris et al., 2007), this would be an interesting 
analysis for future studies. 
At present it is not known which substance in the salmon is responsible for the 
treatment effect. These studies could provide the basis for more specific diet 
interventions, with isolated compounds from the salmon-based diet, like vitamin D-
supplementation. Analyses of vitamin D levels in the different diets used in our study 
show, however, that the cod liver oil diet actually had a higher level of vitamin D than 
the salmon-based diet. This could indicate that vitamin D is not as important in the 
cuprizone model as in EAE. Since the 25-hydroxylation of vitamin D is performed by 
the mitochondrial CYP27A1 isozyme and cuprizone is known to inhibit a number of 
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mitochondrial enzymes, the effects of vitamin D could have been inhibited by 
cuprizone. More studies of vitamin D supplementation in the cuprizone model, 
preferably with measures of 25-(OH)D3 serum levels, should be performed.  
In our study, salmon was both the lipid and protein source in the salmon-cuprizone 
group. It would also be interesting to feed mice only the lipid fraction in salmon in 
order to exclude an interaction with the proteins. It has also been speculated if 
antioxidants could have a protective effect in the cuprizone model (Zhang et al., 2008) 
as well as in EAE (Hendriks et al., 2004). This indicates that another interesting 
candidate could be the antioxidant astaxanthin. Salmon is known to contain large 
amounts of astaxanthin and this substance could be a possible candidate for future 
pharmaceutical interventions (Jackson et al., 2008). 
Paper III 
This case study supports the theory that early childhood or the intrauterine periods are 
the main susceptibility periods for low levels of vitamin D. To date, no association 
study on VDDR1, or other forms of rickets, and MS has been conducted. Since 
VDDR1 is a very rare disease, such association studies would be difficult to perform 
in most parts of the world. It has, however, been estimated to affect 1 in 2916 children 
in the Saguenay-Lac-St-Jean region of Quebec, Canada (De Braekeleer and 
Larochelle, 1991) and this region would have been particularly interesting for this kind 
of studies. Finally, it would have been interesting to perform studies on the association 
between other forms of childhood rickets and the risk of MS.  
Paper IV 
EBV remains one of the key candidates in the pathogenesis of MS. Our study is the 
second to conclude that EBV reactivation is not associated with MS exacerbations and 
our results are also in accordance with the findings from a recent study (Farrell et al., 
2009). The association found by Wandinger and colleagues (Wandinger et al., 2000) 
may be an occasional association in a small sample set. Larger study samples that 
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include measures of both PCR and serology may be necessary to fully determine this 
possible association.  
Paper V 
Microarray-based studies offer the potential to discover disease specific alterations in 
gene expression and give a better understanding of the molecular pathomechanisms in 
MS. More studies are needed to replicate the findings from these studies and to 
hopefully generate new targets for disease intervention. Since we were unable to 
identify genes differentially expressed between grey matter lesions and normal 
appearing grey matter in MS samples, there is also need for more microarray studies 
comparing grey matter and grey matter lesions, preferably with laser dissected 
material.  
In our study, very few plasma cells seem to be responsible for the Ig upregulation. 
Since recent findings have indicated that EBV-persistence and reactivation in the CNS 
could be important for development and disease progression in MS, more studies on 
this subject are warranted. The few plasma- and B-lymphocytes we found present in 
the cortical sections, indicate that a very sensitive method is probably necessary to 
detect the presence of EBV infected cells in MS patients. Thus, the reason for the 
discrepant findings could be caused by a low sensitivity of the methods used in the 
negative studies. Another possible reason for the discrepant findings could be that 
EBV is only present in a subgroup of MS-patients. In other diseases where EBV 
infections are known to be an important co-factor, like Burkitt’s lymphoma, EBV is 
only found in about 30-40% of the cases (Kuppers, 2003). Our findings indicate that 
cortical and meningeal EBV infections are not necessary for the Ig-upregulation 
detected in our study. More studies are needed to confirm our results and to elucidate 
if persistent EBV-infections in the CNS are important for subgroups of patients. 
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6. Conclusions 
I-II. The extent of demyelination, macrophage/microglia-infiltration and MRI lesion 
volume was significantly lower in the animals receiving a salmon-based diet, 
compared to the two other experimental groups. These mice had also less 
behavioural changes, with less weight loss, anxiety behaviour and preserved 
total activity levels compared to the other diet groups. Thus, diet modification 
with a salmon based diet as the source of n-3 PUFAs seems to protect against 
demyelination in the cuprizone model. These results were not found in diets with 
purified n-3 or n-6 PUFAs. Our findings indicate that discrepant results in 
previous dietary intervention studies for MS could have been influenced by 
differences in type and source of fatty acids. Thus, this study provides a basis for 
further studies exploring the potential role of diet intervention in this disease.  
III. We proposed that VDDR1, and possibly other hereditary rickets mutations that 
influence vitamin D metabolism, could be risk factors for MS. All our patients 
have received vitamin D supplementation since their childhood, and this could 
indicate that insufficient vitamin D substitution could be a risk factor for the 
disease. Since the patients have received substitution therapy, our data could 
also be interpreted to be in in accordance with other studies, indicating early 
childhood or the intrauterine period as the main susceptibility periods for low 
levels of vitamin D. 
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IV. All the patients in our study showed evidence of previous EBV-infection. Thus, 
our findings support the hypothesis that previous infections with EBV may 
have a role in the pathogenesis of MS.  We found however, no evidence for an 
association between EBV reactivation and exacerbations in MS. Our study 
suggests that reactivation of latent EBV infection do not play a significant role 
for exacerbations in RRMS. 
V. This study demonstrates that genes involved in the synthesis of Igs are 
upregulated in cortical grey matter lesions in MS patients and that this activation 
seems to be caused by a small number of meningeal plasma cells. Latently EBV-
infected B-lymphocytes seem not to be necessary for this Ig-upregulation. 
Further, our findings indicate that the OCB-producing cells found in the CSF of 
MS patients could have meningeal origin. 
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